"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,CA,A,CA 30823 A,154-534-120-080-043,1889-02-19,1889,CA 30823D A,,CA 30823T A,,SULKY PLOUGH,,COON ALEXANDER,COON ALEXANDER,,https://lens.org/154-534-120-080-043,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
2,CN,A,CN 107150856 A,065-514-386-003-403,2017-09-12,2017,CN 201710124959 A,2017-03-03,US 201615060244 A,2016-03-03,"Liquid container, liquid container lid, and seal arm assembly of container lid","The invention relates to a liquid container, a liquid container lid, and a seal arm assembly of the container lid. The liquid container lid includes a seal arm assembly that stages opening and closing of a vent hole relative to a drink hole so that vapor within the liquid container may be vented to the atmosphere before the drink hole is opened. The liquid container lid and seal arm assembly reduce or eliminate the possibility of a consumer being injured by the hot vapor exiting through the drink hole due to excess gas pressure within the liquid container. The seal arm assembly is operatively connected to a cap of the liquid container lid so that the seal arm assembly is actuated by rotation of the cap. As the cap is turned in one direction, the seal arm assembly opens the vent hole before opening the drink hole. As the cap is turned in a second direction, the seal arm assembly closes the drink hole before closing the vent hole.",IGNITE USA LLC,COON ROBERT C;;GARFIELD ALEXANDER,,https://lens.org/065-514-386-003-403,Patent Application,no,3,2,7,7,0,A47G19/2272;;A47G19/2272;;B65D47/32;;B65D51/1672;;B65D43/02;;B65D43/0202;;B65D43/14;;B65D45/20;;B65D47/06;;B65D51/18;;B65D2251/0018;;B65D2251/0028;;B65D2251/0081;;B65D2251/0087;;B65D2251/009;;B65D2543/00046;;B65D2543/0099,B65D51/16;;B65D43/02,,0,0,,,,ACTIVE
3,CA,A1,CA 2959592 A1,109-683-276-102-031,2017-09-03,2017,CA 2959592 A,2017-03-01,US 201615060244 A,2016-03-03,LID HAVING A DUAL CAMMED SEAL ARM ASSEMBLY,"A liquid container lid includes a seal arm assembly that stages opening and closing of a vent hole relative to a drink hole so that vapor within the liquid container may be vented to the atmosphere before the drink hole is opened. The liquid container lid and seal arm assembly reduce or eliminate the possibility of a consumer being injured by the hot vapor exiting through the drink hole due to excess gas pressure within the liquid container. The seal arm assembly is operatively connected to a cap of the liquid container lid so that the seal arm assembly is actuated by rotation of the cap. As the cap is turned in one direction, the seal arm assembly opens the vent hole before opening the drink hole. As the cap is turned in a second direction, the seal arm assembly closes the drink hole before closing the vent hole.",IGNITE USA LLC,COON ROBERT C;;GARFIELD ALEXANDER,,https://lens.org/109-683-276-102-031,Patent Application,no,0,0,7,7,0,A47G19/2272;;A47G19/2272;;B65D47/32;;B65D51/1672;;B65D43/02;;B65D43/0202;;B65D43/14;;B65D45/20;;B65D47/06;;B65D51/18;;B65D2251/0018;;B65D2251/0028;;B65D2251/0081;;B65D2251/0087;;B65D2251/009;;B65D2543/00046;;B65D2543/0099,B65D43/22;;B65D51/16,,0,0,,,,DISCONTINUED
4,US,B2,US 10227168 B2,133-930-444-773-383,2019-03-12,2019,US 201615060244 A,2016-03-03,US 201615060244 A,2016-03-03,Lid having a dual cammed seal arm assembly,"A liquid container lid includes a seal arm assembly that stages opening and closing of a vent hole relative to a drink hole so that vapor within the liquid container may be vented to the atmosphere before the drink hole is opened. The liquid container lid and seal arm assembly reduce or eliminate the possibility of a consumer being injured by the hot vapor exiting through the drink hole due to excess gas pressure within the liquid container. The seal arm assembly is operatively connected to a cap of the liquid container lid so that the seal arm assembly is actuated by rotation of the cap. As the cap is turned in one direction, the seal arm assembly opens the vent hole before opening the drink hole. As the cap is turned in a second direction, the seal arm assembly closes the drink hole before closing the vent hole.",IGNITE USA LLC,COON ROBERT C;;GARFIELD ALEXANDER,THE COLEMAN COMPANY INC (2016-05-06),https://lens.org/133-930-444-773-383,Granted Patent,yes,9,0,7,7,0,A47G19/2272;;A47G19/2272;;B65D47/32;;B65D51/1672;;B65D43/02;;B65D43/0202;;B65D43/14;;B65D45/20;;B65D47/06;;B65D51/18;;B65D2251/0018;;B65D2251/0028;;B65D2251/0081;;B65D2251/0087;;B65D2251/009;;B65D2543/00046;;B65D2543/0099,B65D47/32;;A47G19/22;;B65D43/02;;B65D43/14;;B65D45/20;;B65D47/06;;B65D51/18,,0,0,,,,ACTIVE
5,US,A1,US 2017/0253397 A1,086-444-533-876-732,2017-09-07,2017,US 201615060244 A,2016-03-03,US 201615060244 A,2016-03-03,Lid Having A Dual Cammed Seal Arm Assembly,"A liquid container lid includes a seal arm assembly that stages opening and closing of a vent hole relative to a drink hole so that vapor within the liquid container may be vented to the atmosphere before the drink hole is opened. The liquid container lid and seal arm assembly reduce or eliminate the possibility of a consumer being injured by the hot vapor exiting through the drink hole due to excess gas pressure within the liquid container. The seal arm assembly is operatively connected to a cap of the liquid container lid so that the seal arm assembly is actuated by rotation of the cap. As the cap is turned in one direction, the seal arm assembly opens the vent hole before opening the drink hole. As the cap is turned in a second direction, the seal arm assembly closes the drink hole before closing the vent hole.",IGNITE USA LLC,COON ROBERT C;;GARFIELD ALEXANDER,THE COLEMAN COMPANY INC (2016-05-06),https://lens.org/086-444-533-876-732,Patent Application,yes,9,15,7,7,0,A47G19/2272;;A47G19/2272;;B65D47/32;;B65D51/1672;;B65D43/02;;B65D43/0202;;B65D43/14;;B65D45/20;;B65D47/06;;B65D51/18;;B65D2251/0018;;B65D2251/0028;;B65D2251/0081;;B65D2251/0087;;B65D2251/009;;B65D2543/00046;;B65D2543/0099,B65D47/32;;A47G19/22;;B65D43/02;;B65D43/14;;B65D45/20;;B65D47/06;;B65D51/18,,0,0,,,,ACTIVE
6,CN,A,CN 111153039 A,066-776-837-155-630,2020-05-15,2020,CN 202010091042 A,2017-03-03,US 201615060244 A;;CN 201710124959 A,2016-03-03,Seal arm assembly for container lid,"The invention relates to a seal arm assembly for a container lid. The seal arm assembly includes: a seal arm pivotably movable about a pivot point; and a rotatable cam having a first cam surface and asecond cam surface, where the second cam surface cooperates with the seal arm to pivot the seal arm about the pivot point. The seal arm assembly is operatively connected to a top lid of the liquid container lid such that rotation of the top lid actuates the seal arm assembly. When the top lid rotates in one direction, the seal arm assembly opens an exhaust hole first and then opens a drinking hole. When the top lid rotates in the second direction, the seal arm assembly firstly closes the drinking hole and then closes the exhaust hole.",IGNITE USA LLC,COON ROBERT C;;GARFIELD ALEXANDER,,https://lens.org/066-776-837-155-630,Patent Application,no,2,0,7,7,0,A47G19/2272;;A47G19/2272;;B65D47/32;;B65D51/1672;;B65D43/02;;B65D43/0202;;B65D43/14;;B65D45/20;;B65D47/06;;B65D51/18;;B65D2251/0018;;B65D2251/0028;;B65D2251/0081;;B65D2251/0087;;B65D2251/009;;B65D2543/00046;;B65D2543/0099,B65D51/16;;B65D43/02,,0,0,,,,ACTIVE
7,EP,A1,EP 3214012 A1,170-134-679-438-058,2017-09-06,2017,EP 17159193 A,2017-03-03,US 201615060224 A,2016-03-03,LID HAVING A DUAL CAMMED SEAL ARM ASSEMBLY,"A liquid container lid (10) includes a seal arm assembly (46) that stages opening and closing of a vent hole (24) relative to a drink hole (26) so that vapor within the liquid container may be vented to the atmosphere before the drink hole is opened. The liquid container lid and seal arm assembly reduce or eliminate the possibility of a consumer being injured by the hot vapor exiting through the drink hole due to excess gas pressure within the liquid container. The seal arm assembly is operatively connected to a cap (14 ) of the liquid container lid so that the seal arm assembly is actuated by rotation of the cap. As the cap is turned in one direction, the seal arm assembly opens the vent hole before opening the drink hole. As the cap is turned in a second direction, the seal arm assembly closes the drink hole before closing the vent hole.
",IGNITE USA LLC,COON ROBERT C;;GARFIELD ALEXANDER,,https://lens.org/170-134-679-438-058,Patent Application,yes,3,6,17,17,0,A47G19/22;;B65D47/244;;B65D47/32;;A47G19/2272;;H01L21/268;;H01L21/3065;;H01L21/32136;;H01L21/76;;H01L21/76811;;H01L21/7682;;H01L21/78;;A47G19/22;;B65D47/244;;B65D47/32;;A47G19/2272;;B23K26/0624;;B23K10/003;;H01L21/78;;H01L23/544;;H01L2223/5446,B65D47/24;;A47G19/22;;B65D47/32,,0,0,,,,DISCONTINUED
8,US,A1,US 2015/0112301 A1,131-685-734-238-080,2015-04-23,2015,US 201314400287 A,2013-05-10,US 201314400287 A;;US 201261645137 P;;US 2013/0040622 W,2012-05-10,APPARATUS AND METHOD FOR ENDOLUMINAL STENT TRANSIT,"An endoluminal stent transit device. The endoluminal stent transit device includes a wire having a distal end and a proximal end, and a guide element attached to the wire at the distal end, which is movable between a first position and a second position. The guide element in the first position is in a contracted configuration while located within a lumen of a catheter and has a first diameter smaller than the catheter, and in the second position is in an expanded configuration while located outside of the lumen of the catheter and has a second diameter larger than the catheter.",UNIV JOHNS HOPKINS,COON ALEXANDER LEWIS;;COLBY GEOFFREY PHILIP,THE JOHNS HOPKINS UNIVERSITY (2013-06-17),https://lens.org/131-685-734-238-080,Patent Application,yes,2,0,2,2,0,A61F2/82;;A61F2/95;;A61F2/958;;A61F2002/823;;A61F2002/9505;;A61F2/958;;A61F2002/9505;;A61F2/95;;A61F2002/823;;A61F2/82;;A61M25/0905;;A61M2025/09008;;A61M2025/09175,A61M25/09,604/506;;604/164.13;;604/96.01,0,0,,,,DISCONTINUED
9,WO,A1,WO 2013/170196 A1,016-729-147-886-967,2013-11-14,2013,US 2013/0040622 W,2013-05-10,US 201261645137 P,2012-05-10,APPARATUS AND METHOD FOR ENDOLUMINAL STENT TRANSIT,"An endoluminal stent transit device. The endoluminal stent transit device includes a wire having a distal end and a proximal end, and a guide element attached to the wire at the distal end, which is movable between a first position and a second position. The guide element in the first position is in a contracted configuration while located within a lumen of a catheter and has a first diameter smaller than the catheter, and in the second position is in an expanded configuration while located outside of the lumen of the catheter and has a second diameter larger than the catheter.",UNIV JOHNS HOPKINS,COON ALEXANDER LEWIS;;COLBY GEOFFREY PHILIP,,https://lens.org/016-729-147-886-967,Patent Application,yes,5,1,2,2,0,A61F2/82;;A61F2/95;;A61F2/958;;A61F2002/823;;A61F2002/9505;;A61F2/958;;A61F2002/9505;;A61F2/95;;A61F2002/823;;A61F2/82;;A61M25/0905;;A61M2025/09008;;A61M2025/09175,A61F2/07;;A61F2/06;;A61F2/86;;A61M25/01,,0,0,,,,PENDING
10,US,A1,US 2022/0365028 A1,091-006-182-803-662,2022-11-17,2022,US 202217741277 A,2022-05-10,US 202217741277 A;;US 202163187190 P,2021-05-11,"QUANTITATIVE SHOTGUN PROTEOME, LIPIDOME, AND METABOLOME ANALYSIS BY DIRECT INFUSION","The present invention provides methods and systems using gas-phase separation with mass spectrometry analysis instead of liquid chromatography, thereby enabling faster peptide, proteome, and multi-omic analysis. Also provided are improved methods and software for data independent acquisition. One embodiment referred to as Direct Infusion—Shotgun Proteome Analysis (DI-SPA) used with data-independent acquisition mass spectrometry (DIA-MS), resulted in targeted quantification of over 500 proteins within minutes of MS data collection (˜3.5 proteins/second). Enabling fast, unbiased protein and proteome quantification without liquid chromatography, DI-SPA offers a new approach to boosting throughput critical to drug and biomarker discovery studies that require analysis of thousands of proteomes. This invention is also able to perform complex multi-omic analysis of proteomes, lipidomes, and metabolomes on a single platform.",WISCONSIN ALUMNI RES FOUND,MEYER JESSE;;COON JOSHUA;;HEBERT ALEXANDER;;CRANNEY CALEB,,https://lens.org/091-006-182-803-662,Patent Application,yes,0,0,1,1,0,H01J49/0031;;G01N27/623;;G01N27/64;;H01J49/0036;;G01N27/623;;G01N27/624;;H01J49/0031,G01N27/64;;G01N27/623;;G01N27/624;;H01J49/00,,0,0,,,,PENDING
11,WO,A1,WO 1985/005006 A1,025-684-759-979-128,1985-11-07,1985,US 8500537 W,1985-03-29,US 60287984 A,1984-04-23,DUAL IN-LINE PACKAGE CARRIER ASSEMBLY,"DIP carrier assembly comprises carrier (10) having support surface (12) with apertures (13) therethrough to channels (22) in side and bottom of carrier into which DIP leads (4) are formed. Terminals (50) aligned in channels (37) in opposed sidewalls (36) of socket (30) apply releasing force on carrier when DIP leads deflect contact portions (56) of terminals. Release of resilient latch (40, 41) on socket causes ejection of carrier.",AMP INC,COLLER JAMES RAY;;COON PAUL ALEXANDER;;GOODMAN JOSEPH RAY,,https://lens.org/025-684-759-979-128,Patent Application,yes,5,2,3,3,0,H05K7/1046;;H05K7/1046,H05K7/10,H2E ECCC          ECCC203;;H2E ECD           ECD233;;H2E E203          ECCC203;;H2E E233          ECD233;;U1S S2087;;U1S S2088,0,0,,,,PENDING
12,EP,A1,EP 0177578 A1,092-646-664-725-099,1986-04-16,1986,EP 85901853 A,1985-03-29,US 60287984 A,1984-04-23,DUAL IN-LINE PACKAGE CARRIER ASSEMBLY.,"L'assemblage de support pour un boîtier à double rangée de connexions (DIP) comprend un support (10) possédant une surface d'appui (12) pourvue d'ouvertures (13) traversantes reliées à des canaux (22) sur le côté et sur le fond du support dans lequel sont formés les conducteurs (4) du DIP. Les terminaux (50) alignés dans les canaux (37) dans les parois latérales opposées (36) de la prise (30) exercent une force de dégagement sur le support lorsque les conducteurs du DIP écartent les parties de contact (56) des terminaux. Le dégagement des verrous élastiques (40, 41) sur la prise provoque l'éjection du support.",AMP INC,COLLER JAMES RAY;;COON PAUL ALEXANDER;;GOODMAN JOSEPH RAY,,https://lens.org/092-646-664-725-099,Patent Application,yes,0,0,3,3,0,H05K7/1046;;H05K7/1046,H05K7/10,,1,0,,,See references of WO 8505006A1,DISCONTINUED
13,NO,L,NO 20040757 L,040-416-439-002-804,2004-02-20,2004,NO 20040757 A,2004-02-20,GB 0204898 W;;US 357801 A,2001-11-02,Ekspanderbart ror med beskyttelse av mottaksror med innvendig polert boring.,,WEATHERFORD LAMB,SIMPSON NEIL ANDREW ABERCROMBI;;COON ROBERT JOE;;LAURITZEN ERIC J;;MAGUIRE PATRICK G;;TRAN KHAI;;MACKAY ALEXANDER CRAIG,,https://lens.org/040-416-439-002-804,Abstract,no,0,0,10,35,0,E21B43/105;;E21B43/105,E21B43/10,,0,0,,,,EXPIRED
14,CN,B,CN 102640127 B,071-195-914-106-425,2015-05-13,2015,CN 201080053459 A,2010-09-24,US 2010/0050233 W;;US 56744509 A,2009-09-25,Method for distributing independent memory space in L1 Cache,,NVIDIA CORP,MINKIN ALEXANDER L;;HEINRICH STEVEN JAMES;;SELVANESAN RAJESHWARAN;;COON BRETT W;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART G,,https://lens.org/071-195-914-106-425,Granted Patent,no,0,0,8,8,0,G06F12/084;;G06F12/084;;G06F2212/2515;;G06F2212/2515;;G06F2212/301;;G06F2212/301;;G06F2212/6012;;G06F2212/6012,G06F13/00,,0,0,,,,ACTIVE
15,EP,A4,EP 2480975 A4,026-261-467-757-816,2014-05-21,2014,EP 10819549 A,2010-09-24,US 56744509 A;;US 2010/0050233 W,2009-09-25,CONFIGURABLE CACHE FOR MULTIPLE CLIENTS,,NVIDIA CORP,MINKIN ALEXANDER L;;HEINRICH STEVEN JAMES;;SELVANESAN RAJESHWARAN;;COON BRETT W;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART G,,https://lens.org/026-261-467-757-816,Search Report,no,2,0,8,8,0,G06F12/084;;G06F12/084;;G06F2212/2515;;G06F2212/2515;;G06F2212/301;;G06F2212/301;;G06F2212/6012;;G06F2212/6012,G06F12/08;;G06F13/00,,1,0,,,See also references of WO 2011038253A1,ACTIVE
16,US,B2,US 8595425 B2,145-684-819-804-516,2013-11-26,2013,US 56744509 A,2009-09-25,US 56744509 A,2009-09-25,Configurable cache for multiple clients,"One embodiment of the present invention sets forth a technique for providing a L1 cache that is a central storage resource. The L1 cache services multiple clients with diverse latency and bandwidth requirements. The L1 cache may be reconfigured to create multiple storage spaces enabling the L1 cache may replace dedicated buffers, caches, and FIFOs in previous architectures. A “direct mapped” storage region that is configured within the L1 cache may replace dedicated buffers, FIFOs, and interface paths, allowing clients of the L1 cache to exchange attribute and primitive data. The direct mapped storage region may used as a global register file. A “local and global cache” storage region configured within the L1 cache may be used to support load/store memory requests to multiple spaces. These spaces include global, local, and call-return stack (CRS) memory.",MINKIN ALEXANDER L;;HEINRICH STEVEN JAMES;;SELVANESAN RAJESHWARAN;;COON BRETT W;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART G;;NVIDIA CORP,MINKIN ALEXANDER L;;HEINRICH STEVEN JAMES;;SELVANESAN RAJESHWARAN;;COON BRETT W;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART G,NVIDIA CORPORATION (2009-09-25),https://lens.org/145-684-819-804-516,Granted Patent,yes,9,2,8,8,0,G06F12/084;;G06F12/084;;G06F2212/2515;;G06F2212/2515;;G06F2212/301;;G06F2212/301;;G06F2212/6012;;G06F2212/6012,G06F12/00,711/104;;711/141;;711/117;;711/118;;711/129;;X711E12046,2,1,020-961-679-464-619,10.1109/40.621209,"International Search Report, PCT Appl. No. PCT/US 10/50233, mailed Dec. 16, 2010.;;Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.",ACTIVE
17,US,A1,US 2011/0078367 A1,171-025-199-964-01X,2011-03-31,2011,US 56744509 A,2009-09-25,US 56744509 A,2009-09-25,CONFIGURABLE CACHE FOR MULTIPLE CLIENTS,"One embodiment of the present invention sets forth a technique for providing a L1 cache that is a central storage resource. The L1 cache services multiple clients with diverse latency and bandwidth requirements. The L1 cache may be reconfigured to create multiple storage spaces enabling the L1 cache may replace dedicated buffers, caches, and FIFOs in previous architectures. A “direct mapped” storage region that is configured within the L1 cache may replace dedicated buffers, FIFOs, and interface paths, allowing clients of the L1 cache to exchange attribute and primitive data. The direct mapped storage region may used as a global register file. A “local and global cache” storage region configured within the L1 cache may be used to support load/store memory requests to multiple spaces. These spaces include global, local, and call-return stack (CRS) memory.",MINKIN ALEXANDER L;;HEINRICH STEVEN JAMES;;SELVANESAN RAJESHWAREN;;COON BRETT W;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART G,MINKIN ALEXANDER L;;HEINRICH STEVEN JAMES;;SELVANESAN RAJESHWAREN;;COON BRETT W;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART G,NVIDIA CORPORATION (2009-09-25),https://lens.org/171-025-199-964-01X,Patent Application,yes,6,12,8,8,0,G06F12/084;;G06F12/084;;G06F2212/2515;;G06F2212/2515;;G06F2212/301;;G06F2212/301;;G06F2212/6012;;G06F2212/6012,G06F12/02;;G06F12/00;;G06F12/08,711/104;;711/170;;X711E12001;;X711E12002;;711/118;;X711E12017,0,0,,,,ACTIVE
18,WO,A1,WO 2011/038253 A1,096-524-485-280-776,2011-03-31,2011,US 2010/0050233 W,2010-09-24,US 56744509 A,2009-09-25,CONFIGURABLE CACHE FOR MULTIPLE CLIENTS,"One embodiment of the present invention sets forth a technique for providing a L1 cache that is a central storage resource. The L1 cache services multiple clients with diverse latency and bandwidth requirements. The L1 cache may be reconfigured to create multiple storage spaces enabling the L1 cache may replace dedicated buffers, caches, and FIFOs in previous architectures. A ""direct mapped"" storage region that is configured within the L1 cache may replace dedicated buffers, FIFOs, and interface paths, allowing clients of the L1 cache to exchange attribute and primitive data. The direct mapped storage region may used as a global register file. A ""local and global cache"" storage region configured within the L1 cache may be used to support load/store memory requests to multiple spaces. These spaces include global, local, and call-return stack (CRS) memory.",NVIDIA CORP;;MINKIN ALEXANDER L;;HEINRICH STEVEN JAMES;;SELVANESAN RAJESHWARAN;;COON BRETT W;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART G,MINKIN ALEXANDER L;;HEINRICH STEVEN JAMES;;SELVANESAN RAJESHWARAN;;COON BRETT W;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART G,,https://lens.org/096-524-485-280-776,Patent Application,yes,5,0,8,8,0,G06F12/084;;G06F2212/2515;;G06F2212/301;;G06F2212/6012;;G06F12/084;;G06F2212/6012;;G06F2212/301;;G06F2212/2515,G06F13/00,,0,0,,,,PENDING
19,EP,A1,EP 2480975 A1,100-126-167-563-075,2012-08-01,2012,EP 10819549 A,2010-09-24,US 56744509 A;;US 2010/0050233 W,2009-09-25,CONFIGURABLE CACHE FOR MULTIPLE CLIENTS,,NVIDIA CORP,MINKIN ALEXANDER L;;HEINRICH STEVEN JAMES;;SELVANESAN RAJESHWARAN;;COON BRETT W;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART G,,https://lens.org/100-126-167-563-075,Patent Application,yes,0,0,8,8,0,G06F12/084;;G06F12/084;;G06F2212/2515;;G06F2212/2515;;G06F2212/301;;G06F2212/301;;G06F2212/6012;;G06F2212/6012,G06F12/08;;G06F13/00,,0,0,,,,ACTIVE
20,NO,B1,NO 334091 B1,002-767-482-366-765,2013-12-09,2013,NO 20040757 A,2004-02-20,GB 0204898 W;;US 357801 A,2001-11-02,Ekspanderbart rør med forbedret beskyttelse av innvendig polert gliderør samt fremgangsmåte for plassering av samme,,WEATHERFORD LAMB,SIMPSON NEIL ANDREW ABERCROMBIE;;COON ROBERT JOE;;LAURITZEN ERIC J;;MAGUIRE PATRICK G;;TRAN KHAI;;MACKAY ALEXANDER CRAIG,,https://lens.org/002-767-482-366-765,Granted Patent,no,0,0,10,35,0,E21B43/105;;E21B43/105,E21B43/10,,0,0,,,,EXPIRED
21,CA,A1,CA 2448691 A1,095-271-476-101-036,2003-05-08,2003,CA 2448691 A,2002-10-28,GB 0204898 W;;US 357801 A,2001-11-02,EXPANDABLE TUBULAR HAVING IMPROVED POLISHED BORE RECEPTACLE PROTECTION,"The present invention provides an expandable tubular having improved polishe d bore receptacle protection. The present invention further provides methods f or completing a wellbore through the use of an expandable string of casing havi ng improved polished bore receptacle protection. In one aspect, the invention includes a liner member (200) having an expandable section (225), and a polished bore receptacle (25) positioned below the expandable section. The expandable section is run into a wellbore (205), and is positioned to overla p with the bottom portion of a string of casing (210) already set within the wellbore. The expandable section is then expanded into frictional engagement with the surrounding casing. The expandable section optionally includes at least one sealing member (260) and at least one slip member (270) on the out er surface. In one aspect, a transition section (275) is provided between the expandable section and the polished bore receptacle. The transition section defines a sloped inner diameter which provides further protection for the sealing surfaces of the polished bore receptacle as tools, fluid, and tubula rs are transited downhole through the polished bore receptacle.",WEATHERFORD LAMB,SIMPSON NEIL ANDREW ABERCROMBI;;MAGUIRE PATRICK G;;COON ROBERT JOE;;TRAN KHAI;;LAURITZEN J ERIC;;MACKAY ALEXANDER CRAIG,,https://lens.org/095-271-476-101-036,Patent Application,no,0,0,10,35,0,E21B43/105;;E21B43/105,E21B43/10,,0,0,,,,EXPIRED
22,GB,A,GB 2392940 A,069-346-301-884-375,2004-03-17,2004,GB 0326994 A,2002-10-28,GB 0204898 W;;US 357801 A,2001-11-02,Expandable tubular having improved polished bore receptacle prtection,"The present invention provides an expandable tubular having improved polished bore receptacle protection. The present invention further provides methods for completing a wellbore through the use of an expandable string of casing having improved polished bore receptacle protection. In one aspect, the invention includes a liner member (200) having an expandable section (225), and a polished bore receptacle (25) positioned below the expandable section. The expandable section is run into a wellbore (205), and is positioned to overlap with the bottom portion of a string of casing (210) already set within the wellbore. The expandable section is then expanded into frictional engagement with the surrounding casing. The expandable section optionally includes at least one sealing member (260) and at least one slip member (270) on the outer surface. In one aspect, a transition section (275) is provided between the expandable section and the polished bore receptacle. The transition section defines a sloped inner diameter which provides further protection for the sealing surfaces of the polished bore receptacle as tools, fluid, and tubulars are transited downhole through the polished bore receptacle.",WEATHERFORD LAMB,SIMPSON NEIL ANDREW ABERCROMBI;;MAGUIRE PATRICK G;;COON ROBERT JOE;;LAURITZEN J ERIC;;TRAN KHAI;;MACKAY ALEXANDER CRAIG,,https://lens.org/069-346-301-884-375,Patent Application,no,4,2,10,35,0,E21B43/105;;E21B43/105,E21B43/10,E1F FJR           FJR;;E1F FLA           FLA,0,0,,,,EXPIRED
23,GB,B,GB 2392940 B,152-447-380-891-960,2005-01-05,2005,GB 0326994 A,2002-10-28,GB 0204898 W;;US 357801 A,2001-11-02,Expandable tubular having improved polished bore receptacle protection,,WEATHERFORD LAMB,SIMPSON NEIL ANDREW ABERCROMBI;;MAGUIRE PATRICK G;;COON ROBERT JOE;;LAURITZEN J ERIC;;TRAN KHAI;;MACKAY ALEXANDER CRAIG,,https://lens.org/152-447-380-891-960,Granted Patent,no,4,0,10,35,0,E21B43/105;;E21B43/105,E21B43/10,,0,0,,,,EXPIRED
24,CN,A,CN 102640127 A,157-812-199-994-900,2012-08-15,2012,CN 201080053459 A,2010-09-24,US 2010/0050233 W;;US 56744509 A,2009-09-25,Configurable cache for multiple clients,"One embodiment of the present invention sets forth a technique for providing a L1 cache that is a central storage resource. The L1 cache services multiple clients with diverse latency and bandwidth requirements. The L1 cache may be reconfigured to create multiple storage spaces enabling the L1 cache may replace dedicated buffers, caches, and FIFOs in previous architectures. A ""direct mapped"" storage region that is configured within the L1 cache may replace dedicated buffers, FIFOs, and interface paths, allowing clients of the L1 cache to exchange attribute and primitive data. The direct mapped storage region may used as a global register file. A ""local and global cache"" storage region configured within the L1 cache may be used to support load/store memory requests to multiple spaces. These spaces include global, local, and call-return stack (CRS) memory.",NVIDIA CORP,MINKIN ALEXANDER L;;JAMES HEINRICH STEVEN;;RAJESHWARAN SELVANESAN;;COON BRETT W;;CHARLES MCCARVER;;ANJANA RAJENDRAN;;CARLTON STEWART G,,https://lens.org/157-812-199-994-900,Patent Application,no,2,6,8,8,0,G06F12/084;;G06F12/084;;G06F2212/2515;;G06F2212/2515;;G06F2212/301;;G06F2212/301;;G06F2212/6012;;G06F2212/6012,G06F13/00,,0,0,,,,ACTIVE
25,DE,T1,DE 03783241 T1,049-440-231-935-055,2006-02-09,2006,DE 03783241 T,2003-11-07,US 42522502 P;;US 45426303 P;;US 0335565 W,2002-11-08,SITZKISSENHALTER FÜR EINEN KLAPPSITZ,,JOHNSON CONTROLS TECH CO,WHITE L;;KING J;;CEMALOVIC VANJA;;COLJA RENATO;;MCMILLEN ROBERT;;JONES BARRY;;ALEXANDER D;;COON ROBERT;;HSU ELLIOT,,https://lens.org/049-440-231-935-055,Patent Application,no,0,0,10,20,0,B60N2/01525;;B60N2/01583;;B60N2/206;;B60N2/3011;;B60N2/3031;;B60N2/3065;;B60N2/3077;;B60N2/309;;B60N2/36;;B60N2/914;;B60N2/986;;B60N2/859;;B60N2/01508;;B60N2/01583;;B60N2/3031;;B60N2/36;;B60N2/01525;;B60N2/309;;B60N2/206;;B60N2/3065;;B60N2/3077;;B60N2/3011;;B60N2/859;;B60N2/986;;B60N2/914,B60N2/015;;B60N2/20;;B60N2/30;;B60N2/48;;B60N2/90,,0,0,,,,PENDING
26,CA,C,CA 2448691 C,177-012-379-118-30X,2008-01-29,2008,CA 2448691 A,2002-10-28,GB 0204898 W;;US 357801 A,2001-11-02,EXPANDABLE TUBULAR HAVING IMPROVED POLISHED BORE RECEPTACLE PROTECTION,"The present invention provides an expandable tubular having improved polishe d bore receptacle protection. The present invention further provides methods f or completing a wellbore through the use of an expandable string of casing havi ng improved polished bore receptacle protection. In one aspect, the invention includes a liner member (200) having an expandable section (225), and a polished bore receptacle (25) positioned below the expandable section. The expandable section is run into a wellbore (205), and is positioned to overla p with the bottom portion of a string of casing (210) already set within the wellbore. The expandable section is then expanded into frictional engagement with the surrounding casing. The expandable section optionally includes at least one sealing member (260) and at least one slip member (270) on the out er surface. In one aspect, a transition section (275) is provided between the expandable section and the polished bore receptacle. The transition section defines a sloped inner diameter which provides further protection for the sealing surfaces of the polished bore receptacle as tools, fluid, and tubula rs are transited downhole through the polished bore receptacle.",WEATHERFORD LAMB,MAGUIRE PATRICK G;;MACKAY ALEXANDER CRAIG;;LAURITZEN J ERIC;;COON ROBERT JOE;;TRAN KHAI;;SIMPSON NEIL ANDREW ABERCROMBI,,https://lens.org/177-012-379-118-30X,Granted Patent,no,0,1,10,35,0,E21B43/105;;E21B43/105,E21B43/10;;E21B17/00;;E21B29/00,,0,0,,,,EXPIRED
27,WO,A1,WO 2003/038237 A1,156-868-039-306-028,2003-05-08,2003,GB 0204898 W,2002-10-28,US 357801 A,2001-11-02,EXPANDABLE TUBULAR HAVING IMPROVED POLISHED BORE RECEPTACLE PROTECTION,"The present invention provides an expandable tubular having improved polished bore receptacle protection. The present invention further provides methods for completing a wellbore through the use of an expandable string of casing having improved polished bore receptacle protection. In one aspect, the invention includes a liner member (200) having an expandable section (225), and a polished bore receptacle (25) positioned below the expandable section. The expandable section is run into a wellbore (205), and is positioned to overlap with the bottom portion of a string of casing (210) already set within the wellbore. The expandable section is then expanded into frictional engagement with the surrounding casing. The expandable section optionally includes at least one sealing member (260) and at least one slip member (270) on the outer surface. In one aspect, a transition section (275) is provided between the expandable section and the polished bore receptacle. The transition section defines a sloped inner diameter which provides further protection for the sealing surfaces of the polished bore receptacle as tools, fluid, and tubulars are transited downhole through the polished bore receptacle.",WEATHERFORD LAMB;;SIMPSON NEIL ANDREW ABERCROMBI;;MAGUIRE PATRICK G;;COON ROBERT JOE;;LAURITZEN J ERIC;;TRAN KHAI;;MACKAY ALEXANDER CRAIG,SIMPSON NEIL ANDREW ABERCROMBI;;MAGUIRE PATRICK G;;COON ROBERT JOE;;LAURITZEN J ERIC;;TRAN KHAI;;MACKAY ALEXANDER CRAIG,,https://lens.org/156-868-039-306-028,Patent Application,yes,4,0,10,35,0,E21B43/105;;E21B43/105,E21B43/10,,0,0,,,,PENDING
28,EP,B1,EP 2480975 B1,199-337-940-246-010,2018-06-13,2018,EP 10819549 A,2010-09-24,US 56744509 A;;US 2010/0050233 W,2009-09-25,CONFIGURABLE CACHE FOR MULTIPLE CLIENTS,,NVIDIA CORP,MINKIN ALEXANDER L;;HEINRICH STEVEN JAMES;;SELVANESAN RAJESHWARAN;;COON BRETT W;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART G,,https://lens.org/199-337-940-246-010,Granted Patent,yes,7,0,8,8,0,G06F12/084;;G06F2212/2515;;G06F2212/301;;G06F2212/6012;;G06F12/084;;G06F2212/6012;;G06F2212/301;;G06F2212/2515,G06F12/084,,0,0,,,,ACTIVE
29,US,A1,US 2006/0091705 A1,129-308-383-273-048,2006-05-04,2006,US 51588505 A,2005-09-01,US 42522502 P;;US 45426303 P;;US 0335565 W;;US 51588505 A,2002-11-08,Seat cushion presenter device for folding seat,"A seat back cushion support presenting device for use in a foldable vehicle seat moves a cushion support member from a position within the seat back frame to a position extended from the seat back frame such that the entire cushion is presented. A pair of presenting members, each including a side bolster support portion, are provided in overlapping arrangement for translation along a presenting device support member and rotation with respect to a cushion support member such that as an activation member moves the presenting members together, the cushion support member is extended along with the side bolster support portions.",JOHNSON CONTROLS TECH CO,WHITE BRENNON;;COLJA RENATO;;MCMILLEN ROBERT;;KING ALAN J;;JONES BARRY;;ALEXANDER DANNY D;;CEMALOVIC VANJA;;COON ROBERT,ADIENT LUXEMBOURG HOLDING S.A.R.L (2017-10-03),https://lens.org/129-308-383-273-048,Patent Application,yes,41,14,10,20,0,B60N2/01525;;B60N2/01583;;B60N2/206;;B60N2/3011;;B60N2/3031;;B60N2/3065;;B60N2/3077;;B60N2/309;;B60N2/36;;B60N2/914;;B60N2/986;;B60N2/859;;B60N2/01508;;B60N2/01583;;B60N2/3031;;B60N2/36;;B60N2/01525;;B60N2/309;;B60N2/206;;B60N2/3065;;B60N2/3077;;B60N2/3011;;B60N2/859;;B60N2/986;;B60N2/914,A47D13/04;;B60N2/015;;B60N2/20;;B60N2/30;;B60N2/48;;B60N2/90,297/6,0,0,,,,EXPIRED
30,US,B2,US 7311358 B2,017-029-251-238-07X,2007-12-25,2007,US 51588505 A,2005-09-01,US 42522502 P;;US 45426303 P;;US 0335565 W;;US 51588505 A,2002-11-08,Seat cushion presenter device for folding seat,"A seat back cushion support presenting device for use in a foldable vehicle seat moves a cushion support member from a position within the seat back frame to a position extended from the seat back frame such that the entire cushion is presented. A pair of presenting members, each including a side bolster support portion, are provided in overlapping arrangement for translation along a presenting device support member and rotation with respect to a cushion support member such that as an activation member moves the presenting members together, the cushion support member is extended along with the side bolster support portions.",JOHNSON CONTROLS TECH CO,WHITE BRENNON;;COLJA RENATO;;MCMILLEN ROBERT;;KING ALAN J;;JONES BARRY;;ALEXANDER DANNY D;;CEMALOVIC VANJA;;COON ROBERT;;HSU ELLIOTT,ADIENT LUXEMBOURG HOLDING S.A.R.L (2017-10-03),https://lens.org/017-029-251-238-07X,Granted Patent,yes,43,26,10,20,0,B60N2/01525;;B60N2/01583;;B60N2/206;;B60N2/3011;;B60N2/3031;;B60N2/3065;;B60N2/3077;;B60N2/309;;B60N2/36;;B60N2/914;;B60N2/986;;B60N2/859;;B60N2/01508;;B60N2/01583;;B60N2/3031;;B60N2/36;;B60N2/01525;;B60N2/309;;B60N2/206;;B60N2/3065;;B60N2/3077;;B60N2/3011;;B60N2/859;;B60N2/986;;B60N2/914,B60N2/015;;A47C3/00;;B60N2/20;;B60N2/30;;B60N2/48;;B60N2/90,297/284.9;;297/284.1,1,0,,,"The International Search Report, based on International Application No. PCT/US03/35565, May 17, 2004, (4 pgs.).",EXPIRED
31,EP,B1,EP 1558460 B1,130-938-900-224-474,2009-07-22,2009,EP 03783241 A,2003-11-07,US 0335565 W;;US 42522502 P;;US 45426303 P,2002-11-08,SEAT CUSHION PRESENTER DEVICE FOR FOLDING SEAT,,JOHNSON CONTROLS TECH CO,WHITE BRENNON L;;KING ALAN J;;CEMALOVIC VANJA;;COLJA RENATO;;MCMILLEN ROBERT;;JONES BARRY;;ALEXANDER DANNY D;;COON ROBERT;;HSU ELLIOT,"ADIENT LUXEMBOURG HOLDING S.A.R.L., LU (2018-07-31)",https://lens.org/130-938-900-224-474,Granted Patent,yes,6,0,10,20,0,B60N2/01525;;B60N2/01583;;B60N2/206;;B60N2/3011;;B60N2/3031;;B60N2/3065;;B60N2/3077;;B60N2/309;;B60N2/36;;B60N2/914;;B60N2/986;;B60N2/859;;B60N2/01508;;B60N2/01583;;B60N2/3031;;B60N2/36;;B60N2/01525;;B60N2/309;;B60N2/206;;B60N2/3065;;B60N2/3077;;B60N2/3011;;B60N2/859;;B60N2/986;;B60N2/914,B60N2/30;;B60N2/015;;B60N2/20;;B60N2/48;;B60N2/90,,0,0,,,,EXPIRED
32,AU,A8,AU 2003/290659 A8,100-280-160-449-902,2004-06-03,2004,AU 2003/290659 A,2003-11-07,US 42522502 P;;US 45426303 P;;US 0335565 W,2002-11-08,Seat cushion presenter device for folding seat,,JOHNSON CONTROLS TECH CO,KING ALAN J;;ALEXANDER DANNY D;;HSU ELLIOT;;MCMILLEN ROBERT;;WHITE BRENNON L;;CEMALOVIC VANJA;;COLJA RENATO;;COON ROBERT;;JONES BARRY,,https://lens.org/100-280-160-449-902,Patent Application,no,0,0,10,20,0,B60N2/01525;;B60N2/01583;;B60N2/206;;B60N2/3011;;B60N2/3031;;B60N2/3065;;B60N2/3077;;B60N2/309;;B60N2/36;;B60N2/914;;B60N2/986;;B60N2/859;;B60N2/01508;;B60N2/01583;;B60N2/3031;;B60N2/36;;B60N2/01525;;B60N2/309;;B60N2/206;;B60N2/3065;;B60N2/3077;;B60N2/3011;;B60N2/859;;B60N2/986;;B60N2/914,B60N2/015;;B60N2/20;;B60N2/30;;B60N2/48;;B60N2/90,,0,0,,,,DISCONTINUED
33,WO,A3,WO 2012/029998 A3,140-178-968-371-917,2012-06-28,2012,JP 2011070669 W,2011-09-05,US 201113225235 A;;US 38015910 P;;US 38015410 P,2010-09-03,MICROCHANNEL-COOLED COILS OF ELECTROMAGNETIC ACTUATORS EXHIBITING REDUCED EDDY-CURRENT DRAG,"Linear and planar motors, as exemplary electromagnetic actuators, are disclosed that have at least one actively cooled coil assembly. An exemplary assembly includes a coil having first and second main surfaces. Also included is a respective thermally conductive cooling plate in thermal contact with at least one main surface of the coil. A coolant passageway is defined in or on each cooling plate, and a liquid coolant passes through the coolant passageway. The coolant passageway has a primary pattern that is coextensive with at least part of the main surface of the coil. The primary pattern can include a secondary pattern producing coolant flow through the coolant passageway in a manner that reduces eddy-current losses in the cooling plate. The coolant passageway desirably includes. An exemplary secondary pattern is serpentine. An exemplary primary pattern is radial or has a radial aspect, such as an X-shaped pattern. The devices provide more effective cooling, with better reliability and ease of maintenance, and reduced eddy-current drag than conventional actuators.",NIPPON KOGAKU KK;;BINNARD MICHAEL B;;COAKLEY SCOTT;;POON ALEX;;TOTSU MASAHIRO;;COON DEREK;;KHO LEONARD;;KESWANI GAURAV;;COOPER ALEXANDER;;PHARAND MICHEL;;BJORK MATT,BINNARD MICHAEL B;;COAKLEY SCOTT;;POON ALEX;;TOTSU MASAHIRO;;COON DEREK;;KHO LEONARD;;KESWANI GAURAV;;COOPER ALEXANDER;;PHARAND MICHEL;;BJORK MATT,,https://lens.org/140-178-968-371-917,Search Report,yes,4,0,6,6,0,H02K41/031;;H02K2201/18;;G03F7/70758;;G03F7/70875;;H02K9/227;;H02K3/24;;H02K9/227;;H02K41/031;;H02K2201/18;;G03F7/70875;;G03F7/70758;;H02K9/227;;H02K9/22,H02K3/24,,0,0,,,,PENDING
34,WO,A3,WO 2004/043207 A3,164-789-803-363-736,2004-07-08,2004,US 0335565 W,2003-11-07,US 42522502 P;;US 45426303 P,2002-11-08,SEAT CUSHION PRESENTER DEVICE FOR FOLDING SEAT,"A seat back cushion support presenting device for use in a foldable vehicle seat moves a cushion support member from a position within the seat back frame to a position extended from the seat back frame such that the entire cushion is presented. A pair of presenting members, each including a side bolster support portion, are provided in overlapping arrangement for translation along a presenting device support member and rotation with respect to a cushion support member such that as an activation member moves the presenting members together, the cushion support member is extended along with the side bolster support portions.",JOHNSON CONTROLS TECH CO;;WHITE BRENNON L;;KING ALAN J;;CEMALOVIC VANJA;;COLJA RENATO;;MCMILLEN ROBERT;;JONES BARRY;;ALEXANDER DANNY D;;COON ROBERT;;HSU ELLIOT,WHITE BRENNON L;;KING ALAN J;;CEMALOVIC VANJA;;COLJA RENATO;;MCMILLEN ROBERT;;JONES BARRY;;ALEXANDER DANNY D;;COON ROBERT;;HSU ELLIOT,,https://lens.org/164-789-803-363-736,Search Report,yes,6,0,10,20,0,B60N2/01525;;B60N2/01583;;B60N2/206;;B60N2/3011;;B60N2/3031;;B60N2/3065;;B60N2/3077;;B60N2/309;;B60N2/36;;B60N2/914;;B60N2/986;;B60N2/859;;B60N2/01508;;B60N2/01583;;B60N2/3031;;B60N2/36;;B60N2/01525;;B60N2/309;;B60N2/206;;B60N2/3065;;B60N2/3077;;B60N2/3011;;B60N2/859;;B60N2/986;;B60N2/914,B60N2/015;;B60N2/20;;B60N2/30;;B60N2/48;;B60N2/90,,0,0,,,,PENDING
35,WO,A2,WO 2012/029998 A2,025-221-662-343-106,2012-03-08,2012,JP 2011070669 W,2011-09-05,US 201113225235 A;;US 38015910 P;;US 38015410 P,2010-09-03,MICROCHANNEL-COOLED COILS OF ELECTROMAGNETIC ACTUATORS EXHIBITING REDUCED EDDY-CURRENT DRAG,"Linear and planar motors, as exemplary electromagnetic actuators, are disclosed that have at least one actively cooled coil assembly. An exemplary assembly includes a coil having first and second main surfaces. Also included is a respective thermally conductive cooling plate in thermal contact with at least one main surface of the coil. A coolant passageway is defined in or on each cooling plate, and a liquid coolant passes through the coolant passageway. The coolant passageway has a primary pattern that is coextensive with at least part of the main surface of the coil. The primary pattern can include a secondary pattern producing coolant flow through the coolant passageway in a manner that reduces eddy-current losses in the cooling plate. The coolant passageway desirably includes. An exemplary secondary pattern is serpentine. An exemplary primary pattern is radial or has a radial aspect, such as an X-shaped pattern. The devices provide more effective cooling, with better reliability and ease of maintenance, and reduced eddy-current drag than conventional actuators.",NIPPON KOGAKU KK;;BINNARD MICHAEL B;;COAKLEY SCOTT;;POON ALEX;;TOTSU MASAHIRO;;COON DEREK;;KHO LEONARD;;KESWANI GAURAV;;COOPER ALEXANDER;;PHARAND MICHEL;;BJORK MATT,BINNARD MICHAEL B;;COAKLEY SCOTT;;POON ALEX;;TOTSU MASAHIRO;;COON DEREK;;KHO LEONARD;;KESWANI GAURAV;;COOPER ALEXANDER;;PHARAND MICHEL;;BJORK MATT,,https://lens.org/025-221-662-343-106,Patent Application,yes,10,11,6,6,0,H02K41/031;;H02K2201/18;;G03F7/70758;;G03F7/70875;;H02K9/227;;H02K3/24;;H02K9/227;;H02K41/031;;H02K2201/18;;G03F7/70875;;G03F7/70758;;H02K9/227;;H02K9/22,H02K3/24,,0,0,,,,PENDING
36,EP,A2,EP 1558460 A2,120-004-677-305-586,2005-08-03,2005,EP 03783241 A,2003-11-07,US 0335565 W;;US 42522502 P;;US 45426303 P,2002-11-08,SEAT CUSHION PRESENTER DEVICE FOR FOLDING SEAT,,JOHNSON CONTROLS TECH CO,WHITE BRENNON L;;KING ALAN J;;CEMALOVIC VANJA;;COLJA RENATO;;MCMILLEN ROBERT;;JONES BARRY;;ALEXANDER DANNY D;;COON ROBERT;;HSU ELLIOT,"ADIENT LUXEMBOURG HOLDING S.A.R.L., LU (2018-07-31)",https://lens.org/120-004-677-305-586,Patent Application,yes,0,0,10,20,0,B60N2/01525;;B60N2/01583;;B60N2/206;;B60N2/3011;;B60N2/3031;;B60N2/3065;;B60N2/3077;;B60N2/309;;B60N2/36;;B60N2/914;;B60N2/986;;B60N2/859;;B60N2/01508;;B60N2/01583;;B60N2/3031;;B60N2/36;;B60N2/01525;;B60N2/309;;B60N2/206;;B60N2/3065;;B60N2/3077;;B60N2/3011;;B60N2/859;;B60N2/986;;B60N2/914,B60N2/015;;B60N2/20;;B60N2/30;;B60N2/48;;B60N2/90,,0,0,,,,EXPIRED
37,DE,D1,DE 60328509 D1,172-022-554-982-080,2009-09-03,2009,DE 60328509 T,2003-11-07,US 42522502 P;;US 45426303 P;;US 0335565 W,2002-11-08,SITZKISSENHALTER FÜR EINEN KLAPPSITZ,,JOHNSON CONTROLS TECH CO,WHITE BRENNON L;;KING ALAN J;;CEMALOVIC VANJA;;COLJA RENATO;;MCMILLEN ROBERT;;JONES BARRY;;ALEXANDER DANNY D;;COON ROBERT;;HSU ELLIOT,,https://lens.org/172-022-554-982-080,Granted Patent,no,0,0,10,20,0,B60N2/01525;;B60N2/01583;;B60N2/206;;B60N2/3011;;B60N2/3031;;B60N2/3065;;B60N2/3077;;B60N2/309;;B60N2/36;;B60N2/914;;B60N2/986;;B60N2/859;;B60N2/01508;;B60N2/01583;;B60N2/3031;;B60N2/36;;B60N2/01525;;B60N2/309;;B60N2/206;;B60N2/3065;;B60N2/3077;;B60N2/3011;;B60N2/859;;B60N2/986;;B60N2/914,B60N2/30;;B60N2/015;;B60N2/20;;B60N2/48;;B60N2/90,,0,0,,,,EXPIRED
38,KR,A,KR 20130108325 A,027-486-855-229-808,2013-10-02,2013,KR 20137008245 A,2011-09-05,US 201113225235 A;;US 38015410 P;;US 38015910 P;;JP 2011070669 W,2010-09-03,MICROCHANNEL-COOLED COILS OF ELECTROMAGNETIC ACTUATORS EXHIBITING REDUCED EDDY-CURRENT DRAG,,NIKON CORP,BINNARD MICHAEL B;;COAKLEY SCOTT;;POON ALEX;;TOTSU MASAHIRO;;COON DEREK;;KHO LEONARD;;KESWANI GAURAV;;COOPER ALEXANDER;;PHARAND MICHEL;;BJORK MATT,,https://lens.org/027-486-855-229-808,Patent Application,no,0,0,6,6,0,H02K41/031;;H02K2201/18;;G03F7/70758;;G03F7/70875;;H02K9/227;;H02K3/24;;H02K9/227;;H02K41/031;;H02K2201/18;;G03F7/70875;;G03F7/70758;;H02K9/227;;H02K9/22,,,0,0,,,,DISCONTINUED
39,AU,A1,AU 2003/290659 A1,059-955-465-755-255,2004-06-03,2004,AU 2003/290659 A,2003-11-07,US 42522502 P;;US 45426303 P;;US 0335565 W,2002-11-08,SEAT CUSHION PRESENTER DEVICE FOR FOLDING SEAT,,JOHNSON CONTROLS TECH CO,CEMALOVIC VANJA;;COLJA RENATO;;MCMILLEN ROBERT;;JONES BARRY;;ALEXANDER DANNY D;;COON ROBERT;;HSU ELLIOT;;WHITE BRENNON L;;KING ALAN J,,https://lens.org/059-955-465-755-255,Patent Application,no,0,0,10,20,0,B60N2/01525;;B60N2/01583;;B60N2/206;;B60N2/3011;;B60N2/3031;;B60N2/3065;;B60N2/3077;;B60N2/309;;B60N2/36;;B60N2/914;;B60N2/986;;B60N2/859;;B60N2/01508;;B60N2/01583;;B60N2/3031;;B60N2/36;;B60N2/01525;;B60N2/309;;B60N2/206;;B60N2/3065;;B60N2/3077;;B60N2/3011;;B60N2/859;;B60N2/986;;B60N2/914,B60N2/015;;B60N2/20;;B60N2/30;;B60N2/48;;B60N2/90,,0,0,,,,DISCONTINUED
40,WO,A2,WO 2004/043207 A2,155-268-773-330-473,2004-05-27,2004,US 0335565 W,2003-11-07,US 42522502 P;;US 45426303 P,2002-11-08,SEAT CUSHION PRESENTER DEVICE FOR FOLDING SEAT,"A seat back cushion support presenting device for use in a foldable vehicle seat moves a cushion support member from a position within the seat back frame to a position extended from the seat back frame such that the entire cushion is presented. A pair of presenting members, each including a side bolster support portion, are provided in overlapping arrangement for translation along a presenting device support member and rotation with respect to a cushion support member such that as an activation member moves the presenting members together, the cushion support member is extended along with the side bolster support portions.",JOHNSON CONTROLS TECH CO;;WHITE BRENNON L;;KING ALAN J;;CEMALOVIC VANJA;;COLJA RENATO;;MCMILLEN ROBERT;;JONES BARRY;;ALEXANDER DANNY D;;COON ROBERT;;HSU ELLIOT,WHITE BRENNON L;;KING ALAN J;;CEMALOVIC VANJA;;COLJA RENATO;;MCMILLEN ROBERT;;JONES BARRY;;ALEXANDER DANNY D;;COON ROBERT;;HSU ELLIOT,,https://lens.org/155-268-773-330-473,Patent Application,yes,10,20,10,20,0,B60N2/01525;;B60N2/01583;;B60N2/206;;B60N2/3011;;B60N2/3031;;B60N2/3065;;B60N2/3077;;B60N2/309;;B60N2/36;;B60N2/914;;B60N2/986;;B60N2/859;;B60N2/01508;;B60N2/01583;;B60N2/3031;;B60N2/36;;B60N2/01525;;B60N2/309;;B60N2/206;;B60N2/3065;;B60N2/3077;;B60N2/3011;;B60N2/859;;B60N2/986;;B60N2/914,B60N2/015;;B60N2/20;;B60N2/30;;B60N2/48;;B60N2/90,,0,0,,,,PENDING
41,US,A1,US 2012/0062866 A1,018-872-469-122-219,2012-03-15,2012,US 201113225235 A,2011-09-02,US 201113225235 A;;US 38015910 P;;US 38015410 P,2010-09-03,MICROCHANNEL-COOLED COILS OF ELECTROMAGNETIC ACTUATORS EXHIBITING REDUCED EDDY-CURRENT DRAG,"Electromagnetic actuators are disclosed having at least one actively cooled coil assembly. Exemplary actuators are linear and planar motors of which the cooled coil assembly has a coil having first and second main surfaces. A respective thermally conductive cooling plate is in thermal contact with at least one main surface of the coil. Defined in or on each cooling plate is a coolant passageway that conducts a liquid coolant. A primary pattern of the coolant passageway is coextensive with at least part of the main surface of the coil. The primary pattern can have a secondary pattern through which coolant flows in a manner reducing eddy-current losses. An exemplary secondary pattern is serpentine. An exemplary primary pattern is radial or has a radial aspect, such as an X-shaped pattern. The devices exhibit reduced eddy-current drag.",BINNARD MICHAEL B;;COAKLEY SCOTT;;POON ALEX KA TIM;;TOTSU MASAHIRO;;COON DEREK;;KHO LEONARD WAI FUNG;;KESWANI GAURAV;;COOPER ALEXANDER;;PHARAND MICHEL;;BJORK MATT;;NIKON CORP,BINNARD MICHAEL B;;COAKLEY SCOTT;;POON ALEX KA TIM;;TOTSU MASAHIRO;;COON DEREK;;KHO LEONARD WAI FUNG;;KESWANI GAURAV;;COOPER ALEXANDER;;PHARAND MICHEL;;BJORK MATT,NKON CORPORATION (2011-10-24),https://lens.org/018-872-469-122-219,Patent Application,yes,0,41,6,6,0,H02K41/031;;H02K2201/18;;G03F7/70758;;G03F7/70875;;H02K9/227;;H02K3/24;;H02K9/227;;H02K41/031;;H02K2201/18;;G03F7/70875;;G03F7/70758;;H02K9/227;;H02K9/22,G03B27/58;;H02K41/02,355/72;;310/12.29;;310/12.06,0,0,,,,DISCONTINUED
42,TW,A,TW 201230626 A,177-160-454-092-918,2012-07-16,2012,TW 100131902 A,2011-09-05,US 38015410 P;;US 38015910 P;;US 201113225235 A,2010-09-03,Microchannel-cooled coils of electromagnetic actuators exhibiting reduced eddy-current drag,"Linear and planar motors, as exemplary electromagnetic actuators, are disclosed that have at least one actively cooled coil assembly. An exemplary assembly includes a coil having first and second main surfaces. Also included is a respective thermally conductive cooling plate in thermal contact with at least one main surface of the coil. A coolant passageway is defined in or on each cooling plate, and a liquid coolant passes through the passageway. The coolant passageway has a primary pattern that is coextensive with at least part of the main surface of the coil. The primary pattern can include a secondary pattern producing coolant flow through the coolant passageway in a manner that reduces eddy-current losses in the cooling plate. The coolant passageway desirably includes. An example secondary pattern is serpentine. An exemplary primary pattern is radial or has a radial aspect, such as a X-shaped pattern. The devices provide more effective cooling, with better reliability and ease of maintenance, and reduced eddy-current drag than conventional actuators.",NIKON CORP,BINNARD MICHAEL B;;COAKLEY SCOTT;;POON ALEX KA TIM;;TOTSU MASAHIRO;;COON DEREK;;KHO LEONARD WAI FUNG;;KESWANI GAURAV;;COOPER ALEXANDER;;PHARAND MICHEL;;BJORK MATT,,https://lens.org/177-160-454-092-918,Patent of Addition,no,0,2,6,6,0,H02K41/031;;H02K2201/18;;G03F7/70758;;G03F7/70875;;H02K9/227;;H02K3/24;;H02K9/227;;H02K41/031;;H02K2201/18;;G03F7/70875;;G03F7/70758;;H02K9/227;;H02K9/22,H02K9/19;;H02K41/02,,0,0,,,,PENDING
43,BR,B1,BR 112016018547 B1,034-535-277-443-555,2023-12-12,2023,BR 112016018547 A,2015-02-12,US 2015/0015674 W;;US 201461939695 P;;US 201462031556 P,2014-02-13,Método para processar informações genômicas,"serviços genômicos de consumidor integrado. a presente invenção fornece uma abordagem inovadora para interação acionada por consumidor com dados de sequenciamento ou informações genômicas. o acesso de dados de sequenciamento, para usuários com uma variedade de acessos e permissões, pode ser mediado por um hub central. o hub também pode facilitar o acesso aos dados de sequenciamento para aplicativos de software de terceiros. o hub também pode fornecer análise de dados ou pode ter acesso aos dados analisados para usar tais dados no fornecimento de uma interface de usuário para um detentor de genoma ou para usuários secundários não detentores do sistema.",ILLUMINA INC,ALEXANDER G DICKINSON;;CHADEL JEROME;;KENNETH G YOCUM;;KENNETH J SHERMAN;;KENNETH R BLOOM;;KEVIN P RHODES;;MATTHEW L POSARD;;NICHOLAS A NELSON;;SOPHIE I COON,,https://lens.org/034-535-277-443-555,Granted Patent,no,0,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/01;;G06F3/048;;G06F3/0486,,0,0,,,,ACTIVE
44,WO,A2,WO 2015/123444 A2,057-650-748-458-875,2015-08-20,2015,US 2015/0015674 W,2015-02-12,US 201461939695 P;;US 201462031556 P,2014-02-13,INTEGRATED CONSUMER GENOMIC SERVICES,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/057-650-748-458-875,Patent Application,yes,17,10,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G16B50/30,,6,6,067-938-552-932-390;;043-373-142-407-052;;025-592-815-885-356;;119-556-800-205-493;;002-299-719-258-355;;043-895-385-051-167,17890440;;10.1373/clinchem.2007.091231;;10.2217/17435889.2.4.459;;17716132;;pmc2453067;;10.1021/ja077082c.s002;;10.1021/ja077082c;;18166054;;12560545;;10.1126/science.1079700;;18451975;;10.1364/ol.33.001026;;10.1073/pnas.0710982105;;pmc2234111;;18216253,"SONI; MELLER, CLIN. CHEM., vol. 53, 2007, pages 1996 - 2001;;HEALY, NANOMED, vol. 2, 2007, pages 459 - 481;;COCKROFT ET AL., J. AM. CHEM. SOC., vol. 130, 2008, pages 818 - 820;;LEVENE ET AL., SCIENCE, vol. 299, 2003, pages 682 - 686;;LUNDQUIST ET AL., OPT. LETT., vol. 33, 2008, pages 1026 - 1028;;KORLACH ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, 2008, pages 1176 - 1181",PENDING
45,BR,A2,BR 112016018547 A2,095-468-332-183-019,2021-04-13,2021,BR 112016018547 A,2015-02-12,US 2015/0015674 W;;US 201461939695 P;;US 201462031556 P,2014-02-13,serviços genômicos de consumidor integrado,"serviços genômicos de consumidor integrado. a presente invenção fornece uma abordagem inovadora para interação acionada por consumidor com dados de sequenciamento ou informações genômicas. o acesso de dados de sequenciamento, para usuários com uma variedade de acessos e permissões, pode ser mediado por um hub central. o hub também pode facilitar o acesso aos dados de sequenciamento para aplicativos de software de terceiros. o hub também pode fornecer análise de dados ou pode ter acesso aos dados analisados para usar tais dados no fornecimento de uma interface de usuário para um detentor de genoma ou para usuários secundários não detentores do sistema.",ILLUMINA INC,ALEXANDER G DICKINSON;;KENNETH J SHERMAN;;KEVIN P RHODES;;JEROME CHADEL;;KENNETH G YOCUM;;KENNETH R BLOOM;;MATTHEW L POSARD;;NICHOLAS A NELSON;;SOPHIE I COON,,https://lens.org/095-468-332-183-019,Patent Application,no,0,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/0486;;G16B50/30,,0,0,,,,ACTIVE
46,EP,A2,EP 3105695 A2,113-924-939-704-316,2016-12-21,2016,EP 15708945 A,2015-02-12,US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,INTEGRATED CONSUMER GENOMIC SERVICES,,ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,"ILLUMINA, INC. (2022-06-15)",https://lens.org/113-924-939-704-316,Patent Application,yes,0,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/0486;;G16B50/30,,0,0,,,,ACTIVE
47,AU,A1,AU 2018/204202 A1,179-479-800-373-681,2018-07-05,2018,AU 2018/204202 A,2018-06-13,AU 2018/204202 A;;AU 2015/217139 A;;US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,Integrated consumer genomic services,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to 5 the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/179-479-800-373-681,Patent Application,no,0,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/0486;;G16B50/30,,0,0,,,,DISCONTINUED
48,KR,A,KR 20160122235 A,183-903-302-847-949,2016-10-21,2016,KR 20167025321 A,2015-02-12,US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,INTEGRATED CONSUMER GENOMIC SERVICES,"본 발명은 시퀀싱 데이터 또는 게놈 정보와의 소비자-구동형 상호작용을 위한 신규한 접근법을 제공한다. 다양한 액세스 및 허가를 갖는 사용자들에 대한 시퀀싱 데이터 액세스는 중앙 허브에 의해 중재될 수 있다. 허브는 또한, 제3자 소프트웨어 애플리케이션에 대해 시퀀싱 데이터로의 액세스를 가능케할 수 있다. 허브는 또한, 데이터 분석을 제공하거나 분석된 데이터에 액세스하여, 게놈 소유자에게 또는 시스템의 비-소유자 2차 사용자에게 사용자 인터페이스를 제공하는데 있어서 이러한 데이터를 이용할 수 있다.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/183-903-302-847-949,Patent Application,no,2,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/0486;;G06F19/00;;G06Q30/02;;G06Q30/06;;G16B50/30,,0,0,,,,ACTIVE
49,BR,A8,BR 112016018547 A8,176-265-146-377-238,2022-12-27,2022,BR 112016018547 A,2015-02-12,US 2015/0015674 W;;US 201461939695 P;;US 201462031556 P,2014-02-13,SERVIÇOS GENÔMICOS DE CONSUMIDOR INTEGRADO,"SERVIÇOS GENÔMICOS DE CONSUMIDOR INTEGRADO. A presente invenção fornece uma abordagem inovadora para interação acionada por consumidor com dados de sequenciamento ou informações genômicas. O acesso de dados de sequenciamento, para usuários com uma variedade de acessos e permissões, pode ser mediado por um hub central. O hub também pode facilitar o acesso aos dados de sequenciamento para aplicativos de software de terceiros. O hub também pode fornecer análise de dados ou pode ter acesso aos dados analisados para usar tais dados no fornecimento de uma interface de usuário para um detentor de genoma ou para usuários secundários não detentores do sistema.",ILLUMINA INC,NICHOLAS A NELSON;;MATTHEW L POSARD;;JEROME CHADEL;;KEVIN P RHODES;;KENNETH G YOCUM;;KENNETH J SHERMAN;;SOPHIE I COON;;KENNETH R BLOOM;;ALEXANDER G DICKINSON,,https://lens.org/176-265-146-377-238,Patent Application,no,0,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/01;;G06F3/048;;G06F3/0486;;G16B50/30,,0,0,,,,ACTIVE
50,CA,A1,CA 2939642 A1,067-259-423-399-177,2015-08-20,2015,CA 2939642 A,2015-02-12,US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,INTEGRATED CONSUMER GENOMIC SERVICES,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/067-259-423-399-177,Patent Application,no,0,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/0486;;G16B50/30,,0,0,,,,PENDING
51,AU,B2,AU 2015/217139 B2,198-147-706-485-538,2018-04-12,2018,AU 2015/217139 A,2015-02-12,US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,Integrated consumer genomic services,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/198-147-706-485-538,Granted Patent,no,1,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/0486;;G16B50/30,,1,1,102-424-807-511-811,10.1007/11595014_34,"YANG Y. et al., 'User Group Modelling Based on User Transactional Data for Personalized Systems', Portuguese Conference on Artificial Intelligence 2005 Dec 5 (pp. 337-347). Springer Berlin Heidelberg.",ACTIVE
52,US,A1,US 2011/0078381 A1,022-729-923-837-437,2011-03-31,2011,US 89047610 A,2010-09-24,US 89047610 A;;US 24604409 P,2009-09-25,Cache Operations and Policies For A Multi-Threaded Client,A method for managing a parallel cache hierarchy in a processing unit. The method including receiving an instruction that includes a cache operations modifier that identifies a level of the parallel cache hierarchy in which to cache data associated with the instruction; and implementing a cache replacement policy based on the cache operations modifier.,HEINRICH STEVEN JAMES;;MINKIN ALEXANDER L;;COON BRETT W;;SELVANESAN RAJESHWARAN;;GLANVILLE ROBERT STEVEN;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART GLENN;;NICKOLLS JOHN R;;FAHS BRIAN,HEINRICH STEVEN JAMES;;MINKIN ALEXANDER L;;COON BRETT W;;SELVANESAN RAJESHWARAN;;GLANVILLE ROBERT STEVEN;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART GLENN;;NICKOLLS JOHN R;;FAHS BRIAN,NVIDIA CORPORATION (2010-09-23),https://lens.org/022-729-923-837-437,Patent Application,yes,9,41,2,2,0,G06F12/0842;;G06F12/0842;;G06F12/0897;;G06F12/0897,G06F12/08;;G06F12/00,711/122;;711/133;;X711E12001;;X711E12024;;X711E12022,0,0,,,,ACTIVE
53,WO,A3,WO 2015/123444 A3,089-111-609-938-244,2015-10-08,2015,US 2015/0015674 W,2015-02-12,US 201461939695 P;;US 201462031556 P,2014-02-13,INTEGRATED CONSUMER GENOMIC SERVICES,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/089-111-609-938-244,Search Report,yes,0,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/0486;;G16B50/30,,2,1,102-424-807-511-811,10.1007/11595014_34,"ANONYMOUS: ""Drag and drop - Wikipedia, the free encyclopedia"", 24 January 2014 (2014-01-24), XP055186807, Retrieved from the Internet <URL:http://en.wikipedia.org/w/index.php?title=Drag_and_drop&oldid=592127371> [retrieved on 20150429];;YILING YANG ET AL: ""User Group Profile Modeling Based on User Transactional Data for Personalized Systems"", 1 January 2005, PROGRESS IN ARTIFICIAL INTELLIGENCE LECTURE NOTES IN COMPUTER SCIENCE;LECTURE NOTES IN ARTIFICIAL INTELLIG ENCE;LNCS, SPRINGER, BERLIN, DE, PAGE(S) 337 - 347, ISBN: 978-3-540-30737-2, XP019025237",PENDING
54,AU,B2,AU 2020/202924 B2,128-289-552-725-002,2022-02-24,2022,AU 2020/202924 A,2020-05-01,AU 2020/202924 A;;AU 2018/204202 A;;AU 2015/217139 A;;US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,Integrated consumer genomic services,"A method for processing genomic information in a genomics environment, the method comprising: after a first user completes a first user transaction using a browser in a graphical user interface, storing first user transaction data in a central repository, wherein the first user 5 transaction includes at least one from the following: view a vendor, view a vendor offering, and purchase a vendor offering; after a second user completes a second user transaction on a second user device, storing second user transaction data in the central repository, wherein the second user transaction includes at least one from the following: view a vendor, view a vendor offering, and purchase a vendor offering; comparing the stored first user transaction data to the second 0 user transaction data to provide a record of overlapping transaction history; pushing a recommendation notification to the second user device in a graphical user interface with a recommended transaction offering based on the record of overlapping transaction history.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/128-289-552-725-002,Granted Patent,no,1,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06Q30/02;;G06Q30/06;;G16B50/30,,4,3,000-732-792-119-994;;102-424-807-511-811;;067-333-867-816-288,10.1016/s0957-4174(03)00138-6;;10.1007/11595014_34;;10.1145/352871.352887,"CHO, Y. H. et al., 'Application of Web usage mining and product taxonomy to collaborative recommendations in e-commerce"", Expert systems with Applications, Vol. 26, No. 2, 2004.;;TUZHILIN, A. 'Towards the next generation of recommender systems', Proceedings of the 1st International Conference on E-Business Intelligence (ICEBI2010), 2010.;;YANG Y. et al., 'User Group Modelling Based on User Transactional Data for Personalized Systems', Portuguese Conference on Artificial Intelligence 2005 Dec 5 (pp. 337-347). Springer Berlin Heidelberg.;;SARWAR, B. et al., 'Analysis of recommendation algorithms for e-commerce', 2000.",ACTIVE
55,CN,A,CN 110955371 A,107-752-916-299-340,2020-04-03,2020,CN 201911037144 A,2015-02-12,CN 201911037144 A;;CN 201580019193 A;;US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,Integrated consumer genomic services,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions,may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/107-752-916-299-340,Patent Application,no,17,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/0486;;G06Q30/02;;G16B50/00;;G16B50/30,,3,0,,,"吕成哲;赵晓明;王起伟;: ""浅谈数据挖掘理论"", 中国西部科技(学术), no. 02, pages 39 - 42;;刘桂香;田登;杨维雄;徐琼;: ""西宁地区丙型肝炎的基因分型与药物治疗关系的研究"", 现代预防医学, no. 04, pages 625 - 626;;杨泽民, 范全润: ""数据挖掘及其应用"", 雁北师范学院学报, no. 01, pages 111 - 112",ACTIVE
56,CN,A,CN 106462337 A,144-376-945-396-065,2017-02-22,2017,CN 201580019193 A,2015-02-12,US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,Integrated consumer genomic services,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use the data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/144-376-945-396-065,Patent Application,no,5,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/0486;;G06Q30/02;;G16B50/30,,0,0,,,,ACTIVE
57,AU,A1,AU 2020/202924 A1,121-177-920-130-184,2020-05-21,2020,AU 2020/202924 A,2020-05-01,AU 2020/202924 A;;AU 2018/204202 A;;AU 2015/217139 A;;US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,Integrated consumer genomic services,"A method for processing genomic information in a genomics environment, the method comprising: after a first user completes a first user transaction using a browser in a graphical user interface, storing first user transaction data in a central repository, wherein the first user 5 transaction includes at least one from the following: view a vendor, view a vendor offering, and purchase a vendor offering; after a second user completes a second user transaction on a second user device, storing second user transaction data in the central repository, wherein the second user transaction includes at least one from the following: view a vendor, view a vendor offering, and purchase a vendor offering; comparing the stored first user transaction data to the second 0 user transaction data to provide a record of overlapping transaction history; pushing a recommendation notification to the second user device in a graphical user interface with a recommended transaction offering based on the record of overlapping transaction history.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/121-177-920-130-184,Patent Application,no,0,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06Q30/02;;G06Q30/06;;G16B50/30,,0,0,,,,ACTIVE
58,CA,C,CA 2939642 C,046-609-036-896-283,2022-05-31,2022,CA 2939642 A,2015-02-12,US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,INTEGRATED CONSUMER GENOMIC SERVICES,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/046-609-036-896-283,Granted Patent,no,0,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G16B50/00;;G06F3/0486;;G16B30/00;;G16B50/30,,0,0,,,,PENDING
59,US,B2,US 9952977 B2,045-512-915-025-620,2018-04-24,2018,US 89047610 A,2010-09-24,US 89047610 A;;US 24604409 P,2009-09-25,Cache operations and policies for a multi-threaded client,A method for managing a parallel cache hierarchy in a processing unit. The method including receiving an instruction that includes a cache operations modifier that identifies a level of the parallel cache hierarchy in which to cache data associated with the instruction; and implementing a cache replacement policy based on the cache operations modifier.,HEINRICH STEVEN JAMES;;MINKIN ALEXANDER L;;COON BRETT W;;SELVANESAN RAJESHWARAN;;GLANVILLE ROBERT STEVEN;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART GLENN;;NICKOLLS JOHN R;;FAHS BRIAN;;NVIDIA CORP,HEINRICH STEVEN JAMES;;MINKIN ALEXANDER L;;COON BRETT W;;SELVANESAN RAJESHWARAN;;GLANVILLE ROBERT STEVEN;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART GLENN;;NICKOLLS JOHN R;;FAHS BRIAN,NVIDIA CORPORATION (2010-09-23),https://lens.org/045-512-915-025-620,Granted Patent,yes,9,17,2,2,0,G06F12/0842;;G06F12/0842;;G06F12/0897;;G06F12/0897,G06F12/00;;G06F12/0842;;G06F12/0897,,0,0,,,,ACTIVE
60,AU,A1,AU 2015/217139 A1,065-732-570-697-033,2016-09-29,2016,AU 2015/217139 A,2015-02-12,US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,Integrated consumer genomic services,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,,https://lens.org/065-732-570-697-033,Patent Application,no,0,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F3/0486;;G16B50/30,,0,0,,,,ACTIVE
61,EP,B1,EP 3105695 B1,066-504-852-821-321,2022-06-01,2022,EP 15708945 A,2015-02-12,US 201461939695 P;;US 201462031556 P;;US 2015/0015674 W,2014-02-13,INTEGRATED CONSUMER GENOMIC SERVICES,,ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME;;POSARD MATTHEW L,"ILLUMINA, INC. (2022-06-15)",https://lens.org/066-504-852-821-321,Granted Patent,yes,1,1,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06Q30/02;;G06F3/0486;;G16B50/00;;G16B50/30;;G16H10/60;;G16H40/63,,0,0,,,,ACTIVE
62,JP,A,JP 2018110015 A,044-777-496-129-245,2018-07-12,2018,JP 2018027661 A,2018-02-20,US 201461939695 P;;US 201462031556 P,2014-02-13,INTEGRATED GENOME SERVICE FOR USER,"PROBLEM TO BE SOLVED: To provide a novel method for user-driven interaction with sequencing data or genome information.SOLUTION: Sequencing data access of user using various access and permission can be mediated by a center hub. The hub can also facilitate access to the sequencing data for third-party software application. The hub can conduct data analysis, or can use such data when providing user interface to a secondary user of the system as a genome owner or a non-owner by accessing analyzed data.SELECTED DRAWING: Figure 1",ILLUMINA INC,NICHOLAS A NELSON;;ALEXANDER G DICKINSON;;KENNETH R BLOOM;;SOPHIE I COON;;KENNETH J SHERMAN;;KENNETH G YOCUM;;KEVIN P RHODES;;JEROME CHADEL;;MATTHEW L POSARD,,https://lens.org/044-777-496-129-245,Patent Application,no,3,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G16B50/30,,2,0,,,"北村 泰彦: ""インターネット上での知的情報統合技術"", 第４７回 知識ベースシステム研究会資料 （ＳＩＧ−ＫＢＳ−９９０４）, JPN6019016212, 27 March 2000 (2000-03-27), JP, pages 97 - 103, ISSN: 0004150282;;加藤 由花: ""オンラインショッピングを対象とした正確性と意外性のバランスを考慮したリコメンダシステム"", 情報処理学会論文誌 第４６巻 ＮＯ．ＳＩＧ１３（ＴＯＤ２７） IPSJ, vol. 第46巻, JPN6019016215, 15 September 2005 (2005-09-15), JP, pages 53 - 64, ISSN: 0004150281",ACTIVE
63,US,A1,US 2015/0227697 A1,193-812-805-349-887,2015-08-13,2015,US 201514621036 A,2015-02-12,US 201514621036 A;;US 201461939695 P;;US 201462031556 P,2014-02-13,INTEGRATED CONSUMER GENOMIC SERVICES,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",IILUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME O;;POSARD MATTHEW L,ILLUMINA INC (2015-12-04),https://lens.org/193-812-805-349-887,Patent Application,yes,3,22,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06F19/00;;G06Q30/02;;G16B50/30,,0,0,,,,ACTIVE
64,US,B2,US 11556958 B2,152-216-876-390-15X,2023-01-17,2023,US 201916549544 A,2019-08-23,US 201916549544 A;;US 201514621036 A;;US 201461939695 P;;US 201462031556 P,2014-02-13,Integrated consumer genomic services,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME O;;POSARD MATTHEW L,ILLUMINA INC (2015-12-04),https://lens.org/152-216-876-390-15X,Granted Patent,yes,47,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G16H10/60;;G06F3/0486;;G06Q30/02;;G16B50/00;;G16B50/30;;G16H40/63,,13,6,046-026-243-504-006;;076-275-623-023-146;;011-412-151-317-583;;008-239-927-157-704;;102-424-807-511-811;;000-732-792-119-994,10.1371/journal.pone.0026624;;22028928;;pmc3197577;;10.1109/tpds.2010.178;;10.1590/s1415-47572004000400035;;pmc3098063;;10.1186/1471-2105-11-259;;20482786;;10.1007/11595014_34;;10.1016/s0957-4174(03)00138-6,"“Drag and Drop”, Wikipedia, the free encyclopediahttp://web.archive.org/web/20131207131429/http://en.wikipedia.org/wiki/Drag_and_drop, Sep. 23, 2013.;;“International Search Report and Written Opinion for Application No. PCT/US15/15674”, dated Aug. 20, 2015.;;Angiuoli, Samuel V., et al., “Resources and Costs for Microbial Sequence Analysis Evaluated Using Virtual Machines and Cloud Computing”, PLOS One, vol. 6, No. 10, Oct. 19, 2011, e26624-e26624.9.;;Anonymous, “Drag and drop—Wikipedia, the free encyclopedia”, XP855186887, Retrieved from the Internet: URL: http://en.wikipedi a.org/w/ index.php?title=Drag_and_drop&oldid=592127371 [retrieved on 2815-84-29], Jan. 24, 2014.;;Ekanayake, Jr. , et al., “Cloud Technologies for Bioinformatics Applications”, IEEE Transactions on Parallel and Distributed Systems, vol. 22, No. 6, Jun. 1, 2011, 998-1011.;;Kitamura, Y., “Intelligent Information Integration Technologies on the Internet”, 47th documents for Knowledge Base system Research JSAI(English abstract only), Mar. 27, 2000, 97-103.;;Oikawa, Marcio Katsumi , et al., “GenFlow: Generic flow for integration, management and analysis of molecular biology data”, Genetics and Molecular Biology, vol. 27, No. 4, Dec. 1, 2004, 691-695.;;Wall, et al., “Cloud computing for comparative genomics”, BMC Bioinformatics 11:259, 2010, 12 pages.;;Yang, et al., “User Group Profile Modeling Based on User Transactional Data for Personalized Systems”, Progress in Artificial Intelligence, Jan. 1, 2005, 337-347.;;Cho, et al., “Application of Web usage mining and product taxonomy to collaborative recommendations in e-commerce”, Expert systems with Applications 26(2), 2004, 233-246.;;Sarwar, et al., “Analysis of recommendation algorithms for e-commerce”, GroupLens Research Group, et al., 2000, 1-10.;;Tuzhilin, “Towards the next generation of recommender systems”, Proceedings of the 1st International Conference on E-Business Intelligence (ICEBI2010), 2010, 1 page.;;AU2018204202, Examination Report No. 2 for standard patent applicaiton, dated Jan. 16, 2020, pp. 1-6.",ACTIVE
65,US,A1,US 2019/0378173 A1,125-884-228-930-327,2019-12-12,2019,US 201916549544 A,2019-08-23,US 201916549544 A;;US 201514621036 A;;US 201461939695 P;;US 201462031556 P,2014-02-13,INTEGRATED CONSUMER GENOMIC SERVICES,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME O;;POSARD MATTHEW L,ILLUMINA INC (2015-12-04),https://lens.org/125-884-228-930-327,Patent Application,yes,3,0,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G06Q30/02;;G16B50/30,,0,0,,,,ACTIVE
66,US,B2,US 10438244 B2,065-408-244-359-94X,2019-10-08,2019,US 201514621036 A,2015-02-12,US 201514621036 A;;US 201461939695 P;;US 201462031556 P,2014-02-13,Integrated consumer genomic services,"The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information. Sequencing data access, for users with a variety of access and permissions, may be mediated by a central hub. The hub may also facilitate access to the sequencing data for third party software applications. The hub may also provide data analysis or may have access to analyzed data to use such data in providing a user interface for a genome owner or for non-owner secondary users of the system.",ILLUMINA INC,NELSON NICHOLAS A;;DICKINSON ALEXANDER G;;BLOOM KENNETH R;;COON SOPHIE I;;SHERMAN KENNETH J;;YOCUM KENNETH G;;RHODES KEVIN P;;CHADEL JEROME O;;POSARD MATTHEW L,ILLUMINA INC (2015-12-04),https://lens.org/065-408-244-359-94X,Granted Patent,yes,38,1,28,28,0,G16B50/00;;G06F3/0486;;G06Q30/0269;;G16B50/30;;G06F3/0486;;G16H40/63;;G16H10/60;;G16B50/00;;G06Q30/0269;;G16B50/30;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G06Q30/0269;;G06Q30/0601;;G16B50/30;;G06Q30/0269;;G16H10/60;;G16H40/63;;G16B50/00;;G06F3/0486;;G16B50/30,G16H10/60;;G06F3/0486;;G06Q30/02;;G16B50/00;;G16B50/30;;G16H40/63,,13,3,046-026-243-504-006;;011-412-151-317-583;;102-424-807-511-811,10.1371/journal.pone.0026624;;22028928;;pmc3197577;;10.1590/s1415-47572004000400035;;10.1007/11595014_34,"Angiuoli, Samuel V. et al., “Resources and Costs for Microbial Sequence Analysis Evaluated Using Virtual Machines and Cloud Computing”, PLOS One, vol. 6, No. 10, Oct. 19, 2011, e26624-e26624.9.;;Anonymous, “Drag and drop—Wikipedia, the free encyclopedia”, XP855186887, Retrieved from the Internet: URL:http://en.wikipedia.org/w/ index.php?title=Drag_and_drop&oldid=592127371 [retrieved on 2815-84-29], Jan. 24, 2014.;;Ekanayake, et al., “Cloud Technologies for Bioniformatics Applications”, IEEE Transactions on Parallel and Distributed Sytems, IEEE Service Center, vol. 22, No. 6, Jun. 1, 2011, 998-1011.;;Oikawa, Marcio K. et al., “GenFlow: Generic flow for integration, management and analysis of molecular biology data”, Genetics and Molecular Biology, vol. 27, No. 4, Dec. 1, 2004, 691-695.;;Wall, et al., “Open Access Methodology Article Cloud Computing for Comparative Genomics”, BMC Bioinformatics, Retrieved from the internet: http://www.biomedcentral.com/content/pdf/1471-2105-11-259.pdf [retrieved on Jun. 11, 2014], Jan. 1, 2010, 259.;;“Drag and Drop”, Wikipedia, the free encyclopediahttp://web.archive.org/web/20131207131429/http://en.wikipedia.org/wiki/Drag_and_drop, Sep. 23, 2013.;;“International Search Report and Written Opinion for Application No. PCT/US15/15674”, dated Aug. 20, 2015.;;Yang, et al., “User Group Profile Modeling Based on User Transactional Data for Personalized Systems”, Progress in Artificial Intelligence, vol. 3808 of the series Lecture Notes in Computer Science, Jan. 1, 2005, 337-347.;;Office Action dated Apr. 11, 2018 from the Canadian Intellectual Property Office.;;Korean Patent Office Notice of Preliminary Rejection dated Oct. 25, 2018 (with English translation).;;CN Patent Application 201580019193.8, First Office Action dated Jan. 23, 2019.;;Kitamura, Y. , “Intelligent Information Integration Technologies on the Internet”, 47th documents for Knowledge Base system Research JSAI(English abstract only), Mar. 27, 2000, 97-103.;;Japanese Office Action with English translation , Application No. 2018-027661, mailed May 13, 2019.",ACTIVE
67,WO,A1,WO 2023/196429 A1,180-347-564-447-538,2023-10-12,2023,US 2023/0017627 W,2023-04-05,US 202263328097 P;;US 202263393405 P,2022-04-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COOK CHRISTOPHER;;COON TIMOTHY RICHARD;;HADIDA RUAH SARA SABINA;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PIERRE FABRICE JEAN DENIS;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/180-347-564-447-538,Patent Application,yes,43,0,1,1,0,A61P11/00;;C07D519/00;;C07D515/08,C07D515/08;;A61P11/00;;C07D519/00,,12,9,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;055-902-435-438-57X;;007-364-858-655-289,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1351/pac199668122193;;10.1002/jps.2600660104;;833720,"CUTTING, G. R ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M ET AL., CELL, vol. 61, 1990, pages 863 - 870;;KEREM, B-S ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J, vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND, vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM, vol. 270, 1995, pages 12347 - 50;;""IUPAC Recommendations"", vol. 68, 1996, PURE & APPL. CHEM, pages: 2193 - 2222;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;""The Clinical and Functional Translation of CFTR (CFTR2"", 15 May 2018, JOHNS HOPKINS UNIVERSITY;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER",PENDING
68,WO,A1,WO 2023/154291 A1,131-123-604-409-406,2023-08-17,2023,US 2023/0012546 W,2023-02-07,US 202263307954 P,2022-02-08,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER R;;BOOKSER BRETT C;;CLEVELAND THOMAS;;COON TIMOTHY R;;GALLANT MICHEL;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;LATERREUR JULIE;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;RAMTOHUL YEEMAN K;;REDDY THUMKUNTA JAGADEESWAR;;SCHULZ BECHARA WILLIAM;;STURINO CLAUDIO;;TRAN JOE A;;VALDEZ LINO;;ZHOU JINGLAN;;GROOTENHUIS PETER,,https://lens.org/131-123-604-409-406,Patent Application,yes,55,0,1,1,0,C07D498/18;;C07D498/22;;A61P11/00,C07D498/18;;A61K31/437;;A61P11/00;;C07D498/22,,29,15,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;007-364-858-655-289;;029-966-049-767-156;;060-421-717-880-984;;003-435-046-077-014;;046-328-268-422-852;;036-319-355-441-595;;094-562-500-767-254;;034-163-404-619-281;;056-530-308-246-913;;019-819-339-794-141;;089-386-545-524-511,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1002/jps.2600660104;;833720;;10.1016/b978-0-12-386009-5.00003-5;;10.1016/j.jcf.2018.05.010;;pmc6436558;;29903467;;32128418;;10.1126/sciadv.aay9669;;pmc7034990;;pmc6881293;;31776420;;10.1038/s41598-019-54158-2;;10.1016/j.jcf.2019.12.009;;31902693;;pmc7052731;;32376628;;10.1124/jpet.120.265595;;31800572;;10.1371/journal.pone.0223954;;pmc6892560;;10.4155/ppa-2017-0009;;28696180;;pmc6362895;;10.3389/fphar.2019.00003;;30761000;;pmc7744356;;33092904;;10.1016/j.ejmech.2020.112888,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M ET AL., CELL, vol. 61, 1990, pages 863 - 870;;KEREM, B-S ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;GHELANISCHNEIDER-FUTSCHIK, ACS PHARMACOL. TRANSL. SCI., vol. 3, 2020, pages 4 - 10;;FIBROSIS, vol. 17, no. 5, 2018, pages 595 - 606;;WUTS, P. G. M.: ""Greene's Protective Groups in Organic Synthesis: Fifth Edition"", 2014, JOHN WILEY AND SONS;;LLOYD: ""The Art, Science and Technology of Pharmaceutical Compounding"", 1999;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;S. L. HARBESONR. D. TUNG: ""Deuterium In Drug Discovery and Development"", ANN. REP. MED. CHEM., vol. 46, 2011, pages 403 - 417;;PHUAN, P.-W ET AL., J. CYST. FIBROS, vol. 17, no. 5, 2018, pages 595 - 606;;PEDEMONTE, N ET AL., SCI. ADV., vol. 6, no. 8, 2020, pages eaay9669;;PHUAN, P.-W. ET AL., SCI. REP., vol. 9, no. 1, 2019, pages 17640;;BOSE, S ET AL., J. CYST. FIBROS., vol. 19, 2020, pages S25 - S32;;CRAWFORD, D.K, J. PHARMACOL. EXP. THER., vol. 374, no. 2, 2020, pages 264 - 272;;BRASELL, E.J. ET AL., PLOS ONE, vol. 14, no. 12, 2019, pages e0223954;;SMITH, N.JSOLOVAY, C.F., PHARM. PAT. ANAL, vol. 6, no. 4, 2017, pages 179 - 188;;KUNZELMANN, K ET AL., FRONT. PHARMACOL, vol. 10, 2019, pages 3;;SON, J.-H ET AL., EUR. J. OF MED. CHEM., 2020, pages 112888;;PEDEMONTE, N ET AL., SCI. ADV, vol. 6, no. 8, 2020, pages eaay9669;;PHUAN, P.-W. ET AL., SCI. REP, vol. 9, no. 1, 2019, pages 17640;;BOSE, S ET AL., J. CYST. FIBROS, vol. 19, 2020, pages S25 - S32;;SON, J.-H ET AL., EUR. J. OF MED. CHEM, 2020, pages 112888;;PHUAN, P.-W. ET AL., J. CYST. FIBROS., vol. 17, no. 5, 2018, pages 595 - 606;;CRAWFORD, D.K., J. PHARMACOL. EXP. THER, vol. 374, no. 2, 2020, pages 264 - 272;;SMITH, N.JSOLOVAY, C.F., PHARM. PAT. ANAL., vol. 6, no. 4, 2017, pages 179 - 188;;KUNZELMANN, K ET AL., FRONT. PHARMACOL., vol. 10, 2019, pages 3;;REMINGTON: ""The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER",PENDING
69,UY,A,UY 39458 A,049-775-903-178-777,2022-05-31,2022,UY 39458 A,2021-10-07,US 202063088759 P,2020-10-07,MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANARIO DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores",VERTEX PHARMA,GROOTENHUIS PETER;;SARA SABINA HADIDA RUAH;;CLEVELAND THOMAS;;BRYAN A FRIEMAN;;KHATUYA HARIPADA;;ZHOU JINGLAN;;ALEXANDER RUSSELL ABELA;;MARK THOMAS MILLER;;MCCARTNEY JASON;;ABRAHAM SUNNY;;COREY DON ANDERSON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;TIMOTHY A DWIGHT;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;PIERRE FABRICE;;SILINA ALINA;;TIMOTHY RICHARD COON;;JOE A TRAN;;PARASELLI PRASUNA,,https://lens.org/049-775-903-178-777,Patent Application,no,0,0,6,6,0,C07D515/04;;A61P43/00;;A61K31/529;;A61K31/5377;;A61K45/06;;C07D515/08;;C07D515/18,A61K31/36;;A61K31/404;;A61K31/443;;A61K31/47;;A61K31/519;;A61P11/00;;C07D515/04;;C07D515/14,,0,0,,,,PENDING
70,US,A1,US 2023/0374038 A1,131-304-294-695-277,2023-11-23,2023,US 202118248068 A,2021-10-06,US 202118248068 A;;US 202063088759 P;;US 2021/0053855 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of mediated diseases, such as cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and therapies comprising such modulators, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS SAN DIEGO (2002-10-22);;VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2021-09-28);;VERTEX PHARMACEUTICALS INCORPORATED (2021-09-21),https://lens.org/131-304-294-695-277,Patent Application,yes,0,0,6,6,0,C07D515/04;;A61P43/00;;A61K31/529;;A61K31/5377;;A61K45/06;;C07D515/08;;C07D515/18,C07D515/08;;A61K31/529;;A61K31/5377;;A61K45/06;;C07D515/18,,0,0,,,,PENDING
71,EP,A1,EP 4225761 A1,195-483-298-254-24X,2023-08-16,2023,EP 21801353 A,2021-10-06,US 202063088759 P;;US 2021/0053855 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;ZHOU JINGLAN,,https://lens.org/195-483-298-254-24X,Patent Application,yes,0,0,6,6,0,C07D515/04;;A61P43/00;;A61K31/529;;A61K31/5377;;A61K45/06;;C07D515/08;;C07D515/18,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
72,TW,A,TW 202229299 A,053-146-799-442-20X,2022-08-01,2022,TW 110137365 A,2021-10-07,US 202063088759 P,2020-10-07,Modulators of Cystic Fibrosis Transmembrane Conductance Regulator,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, such as cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and therapies comprising such modulators, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;ZHOU JINGLAN,,https://lens.org/053-146-799-442-20X,Patent of Addition,no,0,0,6,6,0,C07D515/04;;A61P43/00;;A61K31/529;;A61K31/5377;;A61K45/06;;C07D515/08;;C07D515/18,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
73,CA,A1,CA 3150738 A1,134-802-326-873-471,2021-02-18,2021,CA 3150738 A,2020-08-13,US 201962886611 P;;US 201962886739 P;;US 2020/0046122 W,2019-08-14,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BOOKSER BRETT C;;BUSCH BRETT B;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;TERMIN ANDREAS;;SWIFT SARA E;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/134-802-326-873-471,Patent Application,no,0,0,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,A61K31/435;;A61P11/00;;C07D513/22,,0,0,,,,PENDING
74,AR,A1,AR 123706 A1,003-987-000-762-636,2023-01-04,2023,AR P210102776 A,2021-10-07,US 202063088759 P,2020-10-07,MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANARIO DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores.",VERTEX PHARMA,MCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FRIEMAN BRYAN A;;GROOTENHUIS PETER FALLECIDO;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;ZHOU JINGLAN,,https://lens.org/003-987-000-762-636,Patent Application,no,0,0,6,6,0,C07D515/04;;A61P43/00;;A61K31/529;;A61K31/5377;;A61K45/06;;C07D515/08;;C07D515/18,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
75,WO,A1,WO 2022/076620 A1,170-110-403-166-550,2022-04-14,2022,US 2021/0053855 W,2021-10-06,US 202063088759 P,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, such as cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and therapies comprising such modulators, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FRIEMAN BRYAN A;;GROOTENHUIS PETER (DECEASED);;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;ZHOU JINGLAN,,https://lens.org/170-110-403-166-550,Patent Application,yes,23,4,6,6,0,C07D515/04;;A61P43/00;;A61K31/529;;A61K31/5377;;A61K45/06;;C07D515/08;;C07D515/18,A61K31/519;;C07D515/04;;A61P43/00,,10,8,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;007-364-858-655-289,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1002/jps.2600660104;;833720,"CUTTING, G. R ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, no. 863, 1990, pages 870;;KEREM, B-S ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J, vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND, vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50;;WUTS, P. G. M: ""Greene's Protective Groups in Organic Synthesis: Fifth Edition"", 2014, JOHN WILEY AND SONS;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;""Remington: The Science and Practice of Pharmacy,"", 1988, LIPPINCOTT WILLIAMS & WILKINS",PENDING
76,BR,A2,BR 112022002606 A2,068-158-666-867-530,2022-05-03,2022,BR 112022002606 A,2020-08-13,US 2020/0046122 W;;US 201962886611 P;;US 201962886739 P,2019-08-14,Moduladores do regulador de condutância transmembrana da fibrose cística,"moduladores do regulador de condutância transmembrana da fibrose cística. esta divulgação fornece moduladores do regulador de condutância transmembrana da fibrose cística (cftr), composições farmacêuticas contendo pelo menos um desses moduladores, métodos de tratamento da fibrose cística usando tais moduladores e composições farmacêuticas, e processos para produzir os moduladores.",VERTEX PHARMA,ALEXANDER RUSSELL ABELA;;TERMIN ANDREAS;;ANTON V GULEVICH;;BRETT B BUSCH;;BRETT C BOOKSER;;FRIEMAN BRYAN;;CARL V VOGEL;;COREY DON ANDERSON;;PIERRE FABRICE;;KHATUYA HARIPADA;;MCCARTNEY JASON;;JEREMY J CLEMENS;;ZHOU JINGLAN;;UY JOHNNY;;MARK THOMAS MILLER;;GROOTENHUIS PETER;;PARASELLI PRASUNA;;SARA E SWIFT;;SARA SABINA HADIDA RUAH;;SENAIT G GHIRMAI;;CLEVELAND THOMAS;;TIMOTHY RICHARD COON;;ISHIHARA YOSHIHIRO,,https://lens.org/068-158-666-867-530,Patent Application,no,0,0,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,A61K31/435;;A61P11/00;;C07D513/22,,0,0,,,,PENDING
77,PE,A1,PE 20231951 A1,195-188-900-766-335,2023-12-06,2023,PE 2023001368 A,2021-10-06,US 202063088799 P;;US 2021/0053861 W,2020-10-07,MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUISTICA,"SE REFIERE A COMPUESTOS MACROCICLICOS DE FORMULA (I) DONDE EL ANILLO A Y B, R3, R4, R5, W1, W2, L1, L2, Z Y RYN SON TAL COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: (16R)-12-(2,6-DIMETILFENIL)-15-OXA-8LAMDA6-TIA-1,9,11,18,22-PENTAAZATETRACICLO[14.4.1.13,7.110,14]TRICOSA-3,5,7(23),10,12,14(22)-HEXAENO-2,8,8-TRIONA; (16R)-12-(2,6-DIMETILFENIL)-18-{ESPIRO[3.5]NONAN-2-IL}-15-OXA-8LAMDA6-TIA-1,9,11,18,22-PENTAAZATETRACICLO[14.4.1.13,7.110,14]TRICOSA-3(23),4,6,10(22),11,13-HEXAENO-2,8,8-TRIONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUISTICA (CFTR) SIENDO UTILES EN EL TRATAMIENTO DE FIBROSIS QUISTICA.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH ANDREW;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/195-188-900-766-335,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,A61P43/00;;A61K31/519;;C07D515/04,,0,0,,,,PENDING
78,KR,A,KR 20230104619 A,108-774-887-702-930,2023-07-10,2023,KR 20237015299 A,2021-10-06,US 202063088799 P;;US 2021/0053861 W,2020-10-07,낭성 섬유증 막관통 전도도 조절자의 조절제,"본 개시는 코어 구조 (I)을 갖는 낭성 섬유증 막관통 전도도 조절자(CFTR)의 조절제; 적어도 하나의 이러한 조절제를 함유하는 약학적 조성물; 이러한 조절제 및 약학적 조성물을 사용해, 낭성 섬유증을 포함하는 CFTR 매개 질환을 치료하는 방법; 병용 약학적 조성물 및 병용 요법; 및 이러한 조절제를 제조하기 위한 프로세스 및 중간체를 제공한다. JPEGpct00857.jpg4876 (I)",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH ANDREW;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/108-774-887-702-930,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
79,WO,A1,WO 2022/076625 A1,117-923-415-916-28X,2022-04-14,2022,US 2021/0053861 W,2021-10-06,US 202063088799 P,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH ANDREW;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LINO;;ZHOU JINGLAN;;GROOTENHUIS PETER,,https://lens.org/117-923-415-916-28X,Patent Application,yes,32,4,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,A61P43/00;;A61K31/519;;C07D515/04,,12,9,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;077-295-491-167-117;;007-364-858-655-289,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1002/0471220574;;10.1002/jps.2600660104;;833720,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, 1990, pages 863 - 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P.M, FASEB J., vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50;;WUTS, P. G. M.: ""Greene's Protective Groups in Organic Synthesis"", 2014, JOHN WILEY AND SONS;;LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;REMINGTON: ""The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER",PENDING
80,WO,A1,WO 2021/030556 A1,130-121-203-646-042,2021-02-18,2021,US 2020/0046122 W,2020-08-13,US 201962886611 P;;US 201962886739 P,2019-08-14,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BOOKSER BRETT C;;BUSCH BRETT B;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;TERMIN ANDREAS;;SWIFT SARA E;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN;;GROOTENHUIS PETER,,https://lens.org/130-121-203-646-042,Patent Application,yes,33,9,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,C07D513/22;;A61K31/435;;A61P11/00,,13,10,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;077-295-491-167-117;;007-364-858-655-289;;029-966-049-767-156,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1002/0471220574;;10.1002/jps.2600660104;;833720;;10.1016/b978-0-12-386009-5.00003-5,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, 1990, pages 863 - 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE, vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50;;WUTS, P. G. M.: ""Greene's Protective Groups in Organic Synthesis"", 2014, JOHN WILEY AND SONS;;LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;S. L. HARBESONR. D. TUNG: ""Deuterium In Drug Discovery and Development"", ANN. REP. MED. CHEM., vol. 46, 2011, pages 403 - 417;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER",PENDING
81,EP,A1,EP 4013759 A1,150-896-692-678-975,2022-06-22,2022,EP 20761963 A,2020-08-13,US 201962886611 P;;US 201962886739 P;;US 2020/0046122 W,2019-08-14,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BOOKSER BRETT C;;BUSCH BRETT B;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;TERMIN ANDREAS;;SWIFT SARA E;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN;;GROOTENHUIS PETER,,https://lens.org/150-896-692-678-975,Patent Application,yes,0,0,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,C07D513/22;;A61K31/435;;A61P11/00,,0,0,,,,PENDING
82,KR,A,KR 20220067551 A,177-301-724-902-148,2022-05-24,2022,KR 20227007742 A,2020-08-13,US 201962886611 P;;US 201962886739 P;;US 2020/0046122 W,2019-08-14,낭성 섬유증 막관통 전도도 조절자의 조절제,"본 개시는 낭성 섬유증 막관통 전도도 조절자(CFTR)의 조절제, 적어도 하나의 이러한 조절제를 함유하는 약학적 조성물, 이러한 조절제 및 약학적 조성물을 사용해 낭성 섬유증을 치료하는 방법, 및 이러한 조절제를 제조하는 방법에 관한 것이다.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BOOKSER BRETT C;;BUSCH BRETT B;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;TERMIN ANDREAS;;SWIFT SARA E;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/177-301-724-902-148,Patent Application,no,0,0,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,C07D513/22;;A61K31/403;;A61K31/435;;A61K31/47;;A61P11/00,,0,0,,,,PENDING
83,AU,A1,AU 2021/356651 A1,091-758-667-478-687,2023-05-18,2023,AU 2021/356651 A,2021-10-06,US 202063088799 P;;US 2021/0053861 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH ANDREW;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/091-758-667-478-687,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,A61P43/00;;A61K31/519;;C07D515/04,,0,0,,,,PENDING
84,TW,A,TW 202115094 A,156-273-816-060-69X,2021-04-16,2021,TW 109127758 A,2020-08-14,US 201962886611 P;;US 201962886739 P,2019-08-14,Modulators of Cystic Fibrosis Transmembrane Conductance Regulator,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;DON ANDERSON COREY;;BOOKSER BRETT C;;BUSCH BRETT B;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;TERMIN ANDREAS;;SWIFT SARA E;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/156-273-816-060-69X,Patent of Addition,no,0,0,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,C07D513/22;;A61K31/4375;;A61P11/00,,0,0,,,,PENDING
85,BR,A2,BR 112023006470 A2,066-411-497-119-681,2023-09-26,2023,BR 112023006470 A,2021-10-06,US 2021/0053861 W;;US 202063088799 P,2020-10-07,Moduladores de regulador de condutância transmembrana de fibrose cística,"moduladores de regulador de condutância transmembrana de fibrose cística. esta divulgação fornece moduladores de regulador de condutância transmembrana de fibrose cística (cftr) com a estrutura nuclear (i), composições farmacêuticas contendo pelo menos um referido modulador, métodos de tratamento de doenças mediadas por cftr, incluindo fibrose cística, usando os referidos moduladores e composições farmacêuticas, composições farmacêuticas de combinação e terapias de combinação e processos e intermediários para produzir os referidos moduladores.",VERTEX PHARMA,ALEXANDER RUSSELL ABELA;;SILINA ALINA;;DINH ANDREW;;BRYAN A FRIEMAN;;COREY DON ANDERSON;;PIERRE FABRICE;;CHAU JACLYN;;MCCARTNEY JASON;;CLEMENS JEREMY;;ZHOU JINGLAN;;JOE A TRAN;;LEV TYLER DEWEY FANNING;;VALDEZ LINO;;MARK THOMAS MILLER;;KRENITSKY PAUL;;GROOTENHUIS PETER;;SARA SABINA HADIDA RUAH;;ABRAHAM SUNNY;;CLEVELAND THOMAS;;TIMOTHY A DWIGHT;;TIMOTHY RICHARD COON;;ARUMUGAM VIJAYALAKSMI;;ISHIHARA YOSHIHIRO,,https://lens.org/066-411-497-119-681,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
86,CA,A1,CA 3197173 A1,042-407-398-015-518,2022-04-14,2022,CA 3197173 A,2021-10-06,US 202063088799 P;;US 2021/0053861 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH ANDREW;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LINO;;ZHOU JINGLAN;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA,,https://lens.org/042-407-398-015-518,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,A61K31/519;;A61P43/00;;C07D515/04,,0,0,,,,PENDING
87,EP,A1,EP 4225447 A1,021-216-765-823-151,2023-08-16,2023,EP 21805707 A,2021-10-06,US 202063088799 P;;US 2021/0053861 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH ANDREW;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/021-216-765-823-151,Patent Application,yes,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,A61P43/00;;A61K31/519;;C07D515/04,,0,0,,,,PENDING
88,US,A1,US 2022/0313698 A1,157-403-625-402-668,2022-10-06,2022,US 202016992675 A,2020-08-13,US 202016992675 A;;US 201962886611 P;;US 201962886739 P,2019-08-14,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BOOKSER BRETT C;;BUSCH BRETT B;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;TERMIN ANDREAS;;SWIFT SARA E;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS SAN DIEGO (2002-10-22);;VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2020-08-10);;VERTEX PHARMACEUTICALS INCORPORATED (2020-07-30),https://lens.org/157-403-625-402-668,Patent Application,yes,2,0,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,A61K31/529;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;C07D513/22,,2,0,,,"Dick RM (2011). ""Chapter 2. Pharmacodynamics: The Study of Drug Action"". In Ouellette R, Joyce JA. Pharmacology for Nurse Anesthesiology. Jones & Bartlett Learning:pp. 17-26 (Year: 2011);;J. G. Cannon Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, Volume I: Principles and Practice, Wiley-Interscience 1995, pp. 783-802, 784. (Year: 1995)",PENDING
89,CR,A,CR 20230197 A,175-276-882-224-27X,2023-07-06,2023,CR 20230197 A,2021-10-06,US 202063088799 P;;US 2021/0053861 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tienen la estructura central (I), composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas de combinaciones y terapias combinadas, y procesos y productos intermediarios para producir tales moduladores.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;MCCARTNEY JASON;;ARUMUGAM VIJAYALAKSMI;;DINH ANDREW;;FANNING LEV TYLER DEWEY;;TRAN JOE A;;ANDERSON COREY DON;;CHAU JACLYN;;GROOTENHUIS PETER;;KRENITSKY PAUL;;ABRAHAM SUNNY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;PIERRE FABRICE;;MILLER MARK THOMAS;;SILINA ALINA;;CLEMENS JEREMY;;VALDEZ LINO;;ZHOU JINGLAN;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A,,https://lens.org/175-276-882-224-27X,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,A61P43/00;;A61K31/519;;C07D515/04,,0,0,,,,PENDING
90,UY,A,UY 39459 A,086-241-069-024-148,2022-05-31,2022,UY 39459 A,2021-10-07,US 202063088799 P,2020-10-07,MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANARIO DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores",VERTEX PHARMA,GROOTENHUIS PETER;;SARA SABINA HADIDA RUAH;;CLEVELAND THOMAS;;BRYAN A FRIEMAN;;ZHOU JINGLAN;;ALEXANDER RUSSELL ABELA;;MARK THOMAS MILLER;;MCCARTNEY JASON;;ABRAHAM SUNNY;;COREY DON ANDERSON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;TIMOTHY A DWIGHT;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;PIERRE FABRICE;;SILINA ALINA;;TIMOTHY RICHARD COON;;LEV TYLER DEWEY FANNING;;JOE A TRAN;;VALDEZ LINO;;DINH ANDREW,,https://lens.org/086-241-069-024-148,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,A61K31/36;;A61K31/404;;A61K31/443;;A61K31/47;;A61K31/519;;A61K31/55;;A61P11/00;;C07D515/14,,0,0,,,,PENDING
91,CN,A,CN 116670143 A,011-363-748-097-132,2023-08-29,2023,CN 202180082146 A,2021-10-06,US 202063088799 P;;US 2021/0053861 W,2020-10-07,Modulators of cystic fibrosis transmembrane conductance regulators,"The present disclosure provides modulators of cystic fibrosis transmembrane conductance regulatory factor (CFTR), the modulators having a core structure (I); pharmaceutical compositions containing at least one such modulator; methods of treating CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions; a combination pharmaceutical composition and a combination therapy; and processes and intermediates for preparing such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM STEFFEN;;ANDERSON CHRISTOPHER D;;ARUMUGAM VIDYA;;CHOU JOEY;;CLEMENS JOHN;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH AMANDA;;DWIGHT TERRY A;;FANNING LEV T D;;FREEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YASUO;;KRENITZKY PAVEL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LUIS;;CHOU JOEY,,https://lens.org/011-363-748-097-132,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,C07D515/04,,0,0,,,,PENDING
92,TW,A,TW 202229296 A,040-387-978-466-827,2022-08-01,2022,TW 110137343 A,2021-10-07,US 202063088799 P,2020-10-07,Modulators of Cystic Fibrosis Transmembrane Conductance Regulator,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH ANDREW;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/040-387-978-466-827,Patent of Addition,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
93,AU,A1,AU 2020/328568 A1,042-992-173-812-479,2022-03-03,2022,AU 2020/328568 A,2020-08-13,US 201962886611 P;;US 201962886739 P;;US 2020/0046122 W,2019-08-14,Modulators of cystic fibrosis transmembrane conductance regulator,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BOOKSER BRETT C;;BUSCH BRETT B;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;TERMIN ANDREAS;;SWIFT SARA E;;ZHOU JINGLAN;;UY JOHNNY;;VOGEL CARL V,,https://lens.org/042-992-173-812-479,Patent Application,no,0,0,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,C07D513/22;;A61K31/435;;A61P11/00,,0,0,,,,PENDING
94,US,A1,US 2024/0018161 A1,114-140-321-663-912,2024-01-18,2024,US 202118030530 A,2021-10-06,US 202118030530 A;;US 202063088799 P;;US 2021/0053861 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH ANDREW;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LINO;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS SAN DIEGO (2002-10-22);;VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2021-09-28);;VERTEX PHARMACEUTICALS INCORPORATED (2021-09-21),https://lens.org/114-140-321-663-912,Patent Application,yes,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,C07D515/04;;A61K45/06;;C07D515/14,,0,0,,,,PENDING
95,CN,A,CN 114585628 A,176-748-494-741-389,2022-06-03,2022,CN 202080071733 A,2020-08-13,US 201962886611 P;;US 201962886739 P;;US 2020/0046122 W,2019-08-14,Modulators of cystic fibrosis transmembrane conductance regulator,"The present disclosure provides modulators of cystic fibrosis transmembrane conductance regulatory factor (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treating cystic fibrosis using such modulators and pharmaceutical compositions, and methods for making such modulators.",FEREX PHARMACEUTICAL LTD COMPANY,ABELA ALEXANDER RUSSELL;;ANDERSON CHRISTOPHER D;;BOOKSER BRETT C;;BUSCH BRETT B;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FREEMAN BRYAN;;GILMER STEVE G;;GROOTENHUIS PETER;;GUREVICH ALEKSANDR VLADIMIROVICH;;HADIDA RUAH SARA SABINA;;ISHIHARA YASUO;;KHATUYA HARDIK;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;TERMINI ALESSANDRO;;SWIFT SARA E;;UY JOHNNY;;VOGEL CHRISTIAN V;;CHOU JOEY,,https://lens.org/176-748-494-741-389,Patent Application,no,2,0,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,C07D513/22;;A61K31/439;;A61K31/444;;A61K31/4545;;A61K31/506;;A61P11/00,,0,0,,,,PENDING
96,DO,A,DO P2023000065 A,024-121-126-998-411,2023-07-09,2023,DO 2023000065 A,2023-04-05,US 202063088799 P;;US 2021/0053861 W,2020-10-07,MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tienen la estructura central (I), composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas de combinaciones y terapias combinadas, y procesos y productos intermediarios para producir tales moduladores.",VERTEX PHARMA,MARK THOMAS MILLER;;THOMAS CLEVELAND;;BRYAN A FRIEMAN;;JINGLAN ZHOU;;TIMOTHY RICHARD COON;;VIJAYALAKSMI ARUMUGAM;;JACLYN CHAU;;TIMOTHY A DWIGHT;;SARA SABINA HADIDA RUAH;;PAUL KRENITSKY;;LEV TYLER DEWEY FANNING;;FABRICE PIERRE;;COREY DON ANDERSON;;JEREMY CLEMENS;;PETER GROOTENHUIS (FALLECIDO);;YOSHIHIRO ISHIHARA;;ALINA SILINA;;JOE A TRAN;;LINO VALDEZ;;ALEXANDER RUSELL ABELA;;JASON MCCARTNEY;;SUNNY ABRAHAM;;ANDREW DINH,,https://lens.org/024-121-126-998-411,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,A61K31/519;;A61P43/00;;C07D515/04,,0,0,,,,PENDING
97,AR,A1,AR 123710 A1,113-253-703-930-46X,2023-01-04,2023,AR P210102780 A,2021-10-07,US 202063088799 P,2020-10-07,MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANARIO DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores.",VERTEX PHARMA,MCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAN VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH ANDREW;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER FALLECIDO;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/113-253-703-930-46X,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
98,CL,A1,CL 2023001013 A1,159-603-126-737-622,2023-11-24,2023,CL 2023001013 A,2023-04-06,US 202063088799 P,2020-10-07,Moduladores del regulador de la conductancia transmembrana de la fibrosis quística,"Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tienen la estructura central (I), composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas de combinaciones y terapias combinadas, y procesos y productos intermediarios para producir tales moduladores.",VERTEX PHARMA,THOMAS CLEVELAND;;PETER GROOTENHUIS;;SARA SABINA HADIDA RUAH;;MARK THOMAS MILLER;;LINO VALDEZ;;JINGLAN ZHOU;;JASON MCCARTNEY;;ALEXANDER RUSSELL ABELA;;SUNNY ABRAHAM;;COREY DON ANDERSON;;VIJAYALAKSMI ARUMUGAM;;JACLYN CHAU;;JEREMY CLEMENS;;TIMOTHY RICHARD COON;;TIMOTHY A DWIGHT;;LEV TYLER DEWEY FANNING;;BRYAN A FRIEMAN;;YOSHIHIRO ISHIHARA;;PAUL KRENITSKY;;FABRICE PIERRE;;ALINA SILINA;;JOE A TRAN;;ANDREW DINH,,https://lens.org/159-603-126-737-622,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,A61K31/519;;A61P43/00;;C07D515/04,,0,0,,,,PENDING
99,EP,B1,EP 3752510 B1,011-484-887-763-87X,2022-12-07,2022,EP 19707648 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/011-484-887-763-87X,Granted Patent,yes,1,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,6,2,063-881-765-143-555;;027-103-114-108-370,29251932;;10.1021/acs.jmedchem.7b01339.s002;;10.1021/acs.jmedchem.7b01339;;10.1124/jpet.117.241497;;28611092,"JONATHAN CLAYDEN, NICK GREEVES, STUART WARREN, PETER WOTHERS: ""Organic Chemistry"", 1 January 2001, OXFORD UNIVERSITY PRESS, pages: 143, 144, 340, 341, XP093130416;;ANONYMOUS: ""VX-659/tezacaftor/ivacaftor for Cystic Fibrosis"", 18 January 2017 (2017-01-18), XP093130419, Retrieved from the Internet <URL:https://cysticfibrosisnewstoday.com/vx-659-tezacaftor-ivacaftor-cystic-fibrosis/>;;WANG XUEQING, LIU BO, SEARLE XENIA, YEUNG CLINTON, BOGDAN ANDREW, GRESZLER STEPHEN, SINGH ASHVANI, FAN YIHONG, SWENSEN ANDREW M, V: ""Discovery of 4-[(2 R ,4 R )-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2 H -chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 61, no. 4, 22 February 2018 (2018-02-22), US , pages 1436 - 1449, XP093130421, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.7b01339;;HARBESON SCOTT L., MORGAN ADAM J., LIU JULIE F., ASLANIAN ARA M., NGUYEN SOPHIA, BRIDSON GARY W., BRUMMEL CHRISTOPHER L., WU LIJUN: ""Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development"", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 362, no. 2, 1 August 2017 (2017-08-01), US , pages 359 - 367, XP055981784, ISSN: 0022-3565, DOI: 10.1124/jpet.117.241497;;ARMSTRONG MADELEINE: ""Galapagos goes for broke in cystic fibrosis"", 21 November 2017 (2017-11-21), XP093130423, Retrieved from the Internet <URL:https://www.evaluate.com/vantage/articles/news/galapagos-goes-broke-cystic-fibrosis>;;ARMSTRONG MADELEINE: ""Vertex eyes the treble in cystic fibrosis"", 19 July 2017 (2017-07-19), XP093130424, Retrieved from the Internet <URL:https://www.evaluate.com/vantage/articles/news/vertex-eyes-treble-cystic-fibrosis>",ACTIVE
100,AU,A1,AU 2019/222758 A1,163-604-199-303-111,2020-08-13,2020,AU 2019/222758 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;KHATUYA HARIPADA;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/163-604-199-303-111,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,ACTIVE
101,FI,T3,FI 3752510 T3,197-262-688-458-639,2023-03-14,2023,FI 19707648 T,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/197-262-688-458-639,Unknown,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,,,0,0,,,,PENDING
102,US,A1,US 2022/0106331 A1,018-227-376-379-769,2022-04-07,2022,US 202117323267 A,2021-05-18,US 202117323267 A;;US 201916276350 A;;US 201862631453 P,2018-02-15,"Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2019-02-06);;VERTEX PHARMACEUTICALS INCORPORATED (2019-02-04),https://lens.org/018-227-376-379-769,Patent Application,yes,2,4,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/404;;A61K31/439;;A61K31/47;;A61P11/00;;C07D515/22,,0,0,,,,ACTIVE
103,ZA,B,ZA 202004357 B,194-666-200-219-493,2023-12-20,2023,ZA 202004357 A,2020-07-15,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,JEREMY J CLEMENS;;ALEXANDER RUSSELL ABELA;;COREY DON ANDERSON;;BRETT B BUSCH;;WEICHAO GEORGE CHEN;;THOMAS CLEVELAND;;TIMOTHY RICHARD COON;;BRYAN FRIEMAN;;SENAIT G GHIRMAI;;PETER GROOTENHUIS;;ANTON V GULEVICH;;SARA SABINA HADIDA RUAH;;CLARA KUANG-JU HSIA;;PING KANG;;HARIPADA KHATUYA;;JASON MCCARTNEY;;MARK THOMAS MILLER;;PRASUNA PARASELLI;;FABRICE PIERRE;;SARA E SWIFT;;ANDREAS TERMIN;;JOHNNY UY;;CARL V VOGEL;;JINGLAN ZHOU,,https://lens.org/194-666-200-219-493,Granted Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,,,0,0,,,,ACTIVE
104,SI,T1,SI 3752510 T1,014-291-219-355-369,2023-03-31,2023,SI 201930446 T,2019-02-14,US 201862631453 P;;US 2019/0018042 W;;EP 19707648 A,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/014-291-219-355-369,Granted Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/00;;A61K31/00;;A61P11/00;;C07D515/00,,0,0,,,,ACTIVE
105,MA,A,MA 51828 A,096-801-733-869-997,2020-12-23,2020,MA 51828 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES UTILISÉS EN TANT QUE MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE FIBROSE KYSTIQUE, COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI, LEUR UTILISATION DANS LE TRAITEMENT DE LA FIBROSE KYSTIQUE ET PROCÉDÉ DE FABRICATION ASSOCIÉ",,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/096-801-733-869-997,Unknown,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,A61K31/437;;A61P11/00;;C07D513/22;;C07D515/22,,0,0,,,,ACTIVE
106,HU,T2,HU E061046 T2,120-609-870-841-614,2023-05-28,2023,HU E19707648 A,2019-02-14,US 201862631453 P,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/120-609-870-841-614,Amended Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
107,ES,T3,ES 2939775 T3,098-783-710-392-707,2023-04-26,2023,ES 19707648 T,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"Macrociclos como moduladores del regulador de la conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de los mismos, su uso en el tratamiento de la fibrosis quística, y procesos para elaborarlos","Se describen compuestos de fórmula (I), sales farmacéuticamente aceptables de los mismos, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se describen composiciones farmacéuticas que comprenden las mismas, métodos para tratar la fibrosis quística usando las mismas y métodos para fabricar las mismas. (Traducción automática con Google Translate, sin valor legal)",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/098-783-710-392-707,Granted Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,ACTIVE
108,CO,A2,CO 2022002749 A2,161-409-739-258-336,2022-06-21,2022,CO 2022002749 A,2022-03-09,US 2020/0046122 W;;US 201962886611 P;;US 201962886739 P,2019-08-14,Moduladores del regulador de conductancia transmembrana de la fibrosis quística,"Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de la fibrosis quística mediante el uso de dichos moduladores y composiciones farmacéuticas, y procesos para fabricar dichos moduladores.",VERTEX PHARMA,ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GROOTENHUIS PETER (DECEASED);;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;ISHIHARA YOSHIHIRO;;UY JOHNNY;;BOOKSER BRETT C;;BUSCH BRETT B;;GHIRMAI SENAIT G;;GULEVICH ANTON V;;KHATUYA HARIPADA;;TERMIN ANDREAS;;VOGEL CARL V,,https://lens.org/161-409-739-258-336,Patent Application,no,0,0,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,C07D513/22;;A61K31/435;;A61P11/00,,0,0,,,,PENDING
109,AR,A1,AR 114254 A1,189-264-625-319-040,2020-08-12,2020,AR P190100372 A,2019-02-14,US 201862631453 P,2018-02-15,"MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANA DE FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS, MÉTODOS DE TRATAMIENTO Y PROCESO DE PREPARACIÓN DE LOS MODULADORES","Se revelan compuestos de la fórmula (1), sus sales farmacéuticamente aceptables, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se revelan composiciones farmacéuticas que los comprenden, métodos de tratamiento de fibrosis quística que los usan y métodos para prepararlos. Reivindicación 1: Un compuesto de la fórmula (1), una de sus sales farmacéuticamente aceptables o un derivado deuterado de cualquiera de los anteriores, en donde: Anillo A es un fenilo, un anillo heteroarilo de 5 miembros o un anillo heteroarilo de 6 miembros; Anillo B es un anillo piridinilo; Anillo D es un anillo fenilo, un anillo heterociclilo de 5 miembros, un anillo heterociclilo de 6 miembros, un anillo heteroarilo de 5 miembros o un anillo heteroarilo de 6 miembros; X es O, NH o un N(alquilo C₁₋₄); cada R¹ se selecciona, de modo independiente, de grupos alquilo C₁₋₂, grupos alcoxilo C₁₋₂, grupos haloalquilo C₁₋₂, grupos haloalcoxilo C₁₋₂, halógenos, un grupo ciano y un grupo hidroxilo; m es 0, 1, 2, 3 ó 4; cada R² se selecciona, de modo independiente, de grupos alquilo C₁₋₂, grupos alcoxilo C₁₋₂, grupos haloalquilo C₁₋₂, grupos haloalcoxilo C₁₋₂, halógenos, un grupo ciano y un grupo hidroxilo; n es 0, 1 ó 2; cada R³ es metilo; cada R⁴ se selecciona, de modo independiente, de halógenos, un grupo oxo, un grupo hidroxilo un grupo ciano y grupos -(Y)ₖ-R⁷ u opcionalmente dos R⁴, junto con los átomos a los que están unidos, forman un anillo cicloalquilo o heterociclilo de 5 - 6 miembros que está opcional e independientemente sustituido con uno o más grupos seleccionados de halógenos, grupos alquilo C₁₋₂, grupos haloalquilo, un grupo hidroxilo, grupos alcoxilo C₁₋₂ y grupos haloalcoxilo C₁₋₂; en donde: k es 0, 1, 2, 3, 4, 5 ó 6; cada Y se selecciona, de modo independiente, de grupos C(R⁵)(R⁶), -O- y grupos -NRᵃ-, en donde un heteroátomo en -(Y)ₖ-R⁷ no está ligado con otro heteroátomo en -(Y)ₖ-R⁷, en donde: cada R⁵ y R⁶ se selecciona, de modo independiente, de hidrógeno, halógenos, un grupo hidroxilo, grupos alquilo C₁₋₄ y grupos cicloalquilo C₃₋₅ o R⁵ y R⁶ en el mismo carbono forman un grupo cicloalquilo C₃₋₅ u oxo; cada uno de R⁵ y R⁶ está sustituido opcionalmente, de modo independiente, con uno o más grupos seleccionados de grupos alquilo C₁₋₂, grupos haloalquilo C₁₋₂, halógenos, un grupo hidroxilo, grupos alcoxilo C₁₋₂ y grupos haloalcoxilo C₁₋₂; y cada Rᵃ se selecciona, de modo independiente, de hidrógeno y grupos alquilo C₁₋₂; y R⁷ se selecciona de hidrógeno, halógenos, un grupo ciano y grupos cicloalquilo C₃₋₁₀ opcionalmente sustituidos con uno o más grupos seleccionados de grupos alquilo C₁₋₂, grupos haloalquilo C₁₋₂ y halógenos; q es 1, 2, 3 ó 4; y Z es un ligador divalente de la fórmula (L)ʳ, en donde: r es 1, 2, 3, 4, 5 ó 6; cada L se selecciona, de modo independiente, de grupos C(R⁸)(R⁹), -O- y grupos -NRᵇ-, en donde un heteroátomo en Z no está ligado con otro heteroátomo en Z, en donde: cada R⁸ y R⁹ se selecciona, de modo independiente, de hidrógeno, halógenos, grupos haloalquilo C₁₋₂, grupos alquilo C₁₋₂, un grupo hidroxilo, grupos alcoxilo C₁₋₂ y grupos haloalcoxilo C₁₋₂; y cada Rᵇ se selecciona, de modo independiente, de hidrógeno y grupos alquilo C₁₋₂.",VERTEX PHARMA,HSIA CLARA KUANG;;JU - HADIDA RUAH SARA S;;GULEVICH ANTON V;;GROOTENHUIS PETER;;GHIRMAI SENAIT G;;FRIEMAN BRYAN;;COON TIMOTHY R;;CLEVELAND THOMAS;;CHEN WEICHAO G;;BUSCH BRETT B;;ANDERSON COREY D;;ABELA ALEXANDER R;;CLEMENS JEREMY J;;KANG PING;;KHATUYA HARIPADA;;MCARTNEY JASON;;MILLER MARK T;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/189-264-625-319-040,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/559;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
110,GE,B,GE P20237571 B,104-554-001-104-641,2023-11-27,2023,GE AP2019015439 A,2019-02-14,US 201862631453 P,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM","Present invention relates to macrocyclic compounds of formula (I), (I) pharmaceutically acceptable salts, and deuterated derivatives thereof; pharmaceutical compositions comprising the same, and usage for treating mucoviscidosis are disclosed, as well. s",VERTEX PHARMA,ZHOU JINGLAN;;VOGEL CARL V;;UY JOHNNY;;TERMIN ANDREAS;;SWIFT SARA E;;PIERRE FABRICE;;PARASELLI PRASUNA;;MILLER MARK THOMAS;;MCCARTNEY JASON;;KHATUYA HARIPADA;;KANG PING;;HSIA CLARA KUANG-JU;;HADIDA RUAH SARA SABINA;;GULEVICH ANTON V;;GROOTENHUIS PETER;;GHIRMAI SENAIT G;;FRIEMAN BRYAN;;COON TIMOTHY RICHARD;;CLEVELAND THOMAS;;CHEN WEICHAO GEORGE;;BUSCH BRETT B;;ANDERSON COREY DON;;ABELA ALEXANDER RUSSELL;;CLEMENS JEREMY J,,https://lens.org/104-554-001-104-641,Granted Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,A61P11/00;;A61K31/437;;C07D513/22;;C07D515/22,,0,0,,,,ACTIVE
111,MD,T2,MD 3752510 T2,131-284-166-052-562,2023-06-30,2023,MD E20201268 T,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them","Sunt divulgaţi compuşi cu Formula (I):săruri acceptabile farmaceutic ale acestora, derivaţi deuteraţi ai oricărora dintre cei anteriori, şi metaboliţi ai oricărora dintre cei anteriori. Sunt de asemenea divulgate compoziţii farmaceutice care conţin compuşii, metode pentru tratarea fibrozei chistice care utilizeză compuşii, şi metode de fabricare a acestora.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/131-284-166-052-562,Unknown,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
112,TW,B,TW I780304 B,163-416-544-306-332,2022-10-11,2022,TW 108105209 A,2019-02-15,US 201862631453 P,2018-02-15,"Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/163-416-544-306-332,Granted Patent,no,3,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,,,0,0,,,,ACTIVE
113,JO,A1,JO P20200178 A1,007-268-600-692-816,2022-10-30,2022,JO P20200178 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYSTIC FIBROSIS, AND PROCESS FOR MAKING THEM","<p>Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.</p>",VERTEX PHARMA,PIERRE FABRICE;;KANG PING;;UY JOHNNY;;CHEN WEICHAO GEORGE;;TERMIN ANDREAS;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;HADIDA RUAH SARA SABINA;;BUSCH BRETT B;;SWIFT SARA E;;GULEVICH ANTON V;;FRIEMAN BRYAN;;MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;PARASELLI PRASUNA;;KHATUYA HARIPADA;;ANDERSON COREY DON;;ZHOU JINGLAN;;GROOTENHUIS PETER;;GHIRMAI SENAIT G;;VOGEL CARL V;;COON TIMOTHY RICHARD;;MILLER MARK THOMAS;;HSIA CLARA KUANG-JU,,https://lens.org/007-268-600-692-816,Granted Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,,,0,0,,,,ACTIVE
114,WO,A1,WO 2019/161078 A1,044-853-137-118-415,2019-08-22,2019,US 2019/0018042 W,2019-02-14,US 201862631453 P,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/044-853-137-118-415,Patent Application,yes,21,29,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,19,14,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;077-295-491-167-117;;007-364-858-655-289;;007-364-858-655-289;;002-186-545-851-173;;022-798-051-130-424;;051-512-736-636-159;;023-050-799-689-427,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1002/0471220574;;10.1002/jps.2600660104;;833720;;10.1002/jps.2600660104;;833720;;10.1021/jm4007998;;24294889;;pmc2773991;;10.1073/pnas.0904709106;;19846789;;pmc3219147;;21976485;;10.1073/pnas.1105787108;;10.1056/nejmoa1807119;;pmc6277022;;30334693,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, no. 863, 1990, pages 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528;;PASYK; FOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50;;WUTS, P. G. M.: ""Greene's Protective Groups in Organic Synthesis"", 2014, JOHN WILEY AND SONS;;J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;S. L. HARBESON; R. D. TUNG: ""Deuterium In Drug Discovery and Development"", ANN. REP. MED. CHEM., vol. 46, 2011, pages 403 - 417, XP055422117, DOI: doi:10.1016/B978-0-12-386009-5.00003-5;;T.G. GANT: ""Using deuterium in drug discovery: leaving the label in the drug"", J. MED. CHEM., vol. 57, 2014, pages 3595 - 3611, XP055139522, DOI: doi:10.1021/jm4007998;;""Remington: The Science and Practice of Pharmacy"", LIPPINCOTT WILLIAMS & WILKINS;;""Encyclopedia of Pharmaceutical Technology"", MARCEL DEKKER, pages: 1988 - 1999;;VAN GOOR, F. ET AL., PNAS, vol. 106, no. 44, 2009, pages 18825 - 18830;;VAN GOOR, F. ET AL., PNAS, vol. 108, no. 46, 2011, pages 18843 - 18846;;DAVIES ET AL., NEW ENGL. J. MED., vol. 379, no. 17, 2018, pages 1599 - 1611;;DAVIES ET AL., NEW ENGL. J. MED., vol. 379, no. 17, 2018, pages 1612 - 1620",PENDING
115,EP,A1,EP 4198037 A1,014-213-035-768-157,2023-06-21,2023,EP 22209444 A,2019-02-14,US 201862631453 P;;EP 19707648 A;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS","Compounds of Formula (I):
  
pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/014-213-035-768-157,Patent Application,yes,21,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,18,13,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;002-186-545-851-173;;007-364-858-655-289;;029-966-049-767-156;;022-798-051-130-424;;051-512-736-636-159;;023-050-799-689-427,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1021/jm4007998;;24294889;;10.1002/jps.2600660104;;833720;;10.1016/b978-0-12-386009-5.00003-5;;pmc2773991;;10.1073/pnas.0904709106;;19846789;;pmc3219147;;21976485;;10.1073/pnas.1105787108;;10.1056/nejmoa1807119;;pmc6277022;;30334693,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, no. 863, 1990, pages 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J, vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM, vol. 270, 1995, pages 12347 - 50;;T.G. GANT: ""Using deuterium in drug discovery: leaving the label in the drug"", J. MED. CHEM., vol. 57, 2014, pages 3595 - 3611, XP055139522, DOI: 10.1021/jm4007998;;S. M. BERGE ET AL.: ""describe pharmaceutically acceptable salts in detail in"", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;S. L. HARBESONR. D. TUNG: ""Deuterium In Drug Discovery and Development"", ANN. REP. MED. CHEM, vol. 46, 2011, pages 403 - 417;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER;;VAN GOOR, F. ET AL., PNAS, vol. 106, no. 44, 2009, pages 18825 - 18830;;VAN GOOR, F. ET AL., PNAS, vol. 108, no. 46, 2011, pages 18843 - 18846;;DAVIES ET AL., NEW ENGL. J. MED., vol. 379, no. 17, 2018, pages 1599 - 1611;;DAVIES ET AL., NEW ENGL. J. MED, vol. 379, no. 17, 2018, pages 1612 - 1620",PENDING
116,CN,A,CN 112004817 A,034-560-268-161-534,2020-11-27,2020,CN 201980025942 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositionscomprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/034-560-268-161-534,Patent Application,no,4,2,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,ACTIVE
117,TW,A,TW 201938566 A,081-802-233-166-603,2019-10-01,2019,TW 108105209 A,2019-02-15,US 201862631453 P,2018-02-15,"Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/081-802-233-166-603,Patent of Addition,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/559;;A61P11/00;;C07D515/22,,0,0,,,,ACTIVE
118,EC,A,EC SP20053845 A,068-100-823-066-808,2020-12-31,2020,EC DI202053845 A,2020-09-04,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCICLOS COMO MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS DE ESTOS, SU USO EN EL TRATAMIENTO DE LA FIBROSIS QUÍSTICA Y PROCESOS PARA ELABORARLOS","Se revelan compuestos de la fórmula (I):(FORMULA SE APRECIA EN LA MEMORIA TECNICA) (I), sus sales farmacéuticamente aceptables, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se revelan composiciones farmacéuticas que los comprenden, métodos de tratamiento de fibrosis quística que los usan y métodos para prepararlos.",VERTEX PHARMA,PIERRE FABRICE;;GHIRMAI SENAIT G;;PARASELLI PRASUNA;;MILLER MARK THOMAS;;TERMIN ANDREAS;;VOGEL CARL V;;JASON MCCARTNEY;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;GROOTENHUIS PETER;;UY JOHNNY;;CLEVELAND THOMAS;;GULEVICH ANTON V;;CLEMENS JEREMY J;;KHATUYA HARIPADA;;CHEN WEICHAO GEORGE;;FRIEMAN BRYAN;;KANG PING;;HSIA CLARA KUANG-JU;;BUSCH BRETT B;;SARA SABINA HADIDA RUAH;;COON TIMOTHY RICHARD;;ZHOU JINGLAN;;SWIFT SARA E,,https://lens.org/068-100-823-066-808,Patent Application,no,0,2,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,A61P11/00;;A61K31/437,,0,0,,,,PENDING
119,SG,A,SG 11202006614V A,093-986-167-905-15X,2020-08-28,2020,SG 11202006614V A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/093-986-167-905-15X,Unknown,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
120,CO,A2,CO 2023005736 A2,126-649-439-773-401,2023-09-08,2023,CO 2023005736 A,2023-05-05,US 2021/0053861 W;;US 202063088799 P,2020-10-07,Moduladores del regulador de la conductancia transmembrana de la fibrosis quística,"Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tienen la estructura central (I), composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas de combinaciones y terapias combinadas, y procesos y productos intermediarios para producir tales moduladores.",VERTEX PHARMA,CLEVELAND THOMAS;;PIERRE FABRICE JEAN DENIS;;ANDERSON COREY DON;;COON TIMOTHY RICHARD;;GROOTENHUIS PETER (DECEASED);;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;DWIGHT TIMOTHY A;;FRIEMAN BRYAN A;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;SILINA ALINA;;FANNING LEV TYLER DEWEY;;VALDEZ LINO;;TRAN JOE A;;DINH ANDREW,,https://lens.org/126-649-439-773-401,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,A61P43/00;;A61K31/519;;C07D515/04,,0,0,,,,PENDING
121,KR,A,KR 20200131240 A,068-897-497-128-081,2020-11-23,2020,KR 20207026102 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"낭포성 섬유증 막관통 전도성 조절인자의 조절제로서의 매크로사이클, 그의 약제학적 조성물, 낭포성 섬유증의 치료에서의 그의 용도, 및 그의 제조 방법","하기 화학식 (I)의 화합물, 이의 약학적으로 허용가능한 염, 전술한 것 중 임의의 것의 중수소화된 유도체, 및 전술한 것 중 임의의 것의 대사산물을 개시한다. 또한 이러한 화합물을 포함하는 약학 조성물, 이러한 화합물을 사용하여 낭포성 섬유증을 치료하는 방법, 및 이러한 화합물의 제조 방법을 개시한다. JPEGpct01424.jpg5497",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/068-897-497-128-081,Patent Application,no,2,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/404;;A61K31/439;;A61K31/47;;A61P11/00;;A61P43/00;;C07D515/22,,0,0,,,,ACTIVE
122,LT,T,LT 3752510 T,084-620-821-204-137,2023-04-11,2023,LT US2019018042 T,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/084-620-821-204-137,Unknown,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/404;;A61K31/437;;A61K31/439;;A61K31/47;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
123,BR,A2,BR 112020015509 A2,195-432-151-155-175,2021-01-26,2021,BR 112020015509 A,2019-02-14,US 2019/0018042 W;;US 201862631453 P,2018-02-15,"macrociclos como moduladores de regulador da condutância transmembrana da fibrose cística, composições farmacêuticas dos mesmos, sua utilização no tratamento da fibrose cística, e processo para sua produção","macrociclos como moduladores de regulador da condutância transmembrana da fibrose cística, composições farmacêuticas dos mesmos, sua utilização no tratamento da fibrose cística, e processo para sua produção. a invenção refere-se a compostos da fórmula (i), (r4)q d b (r2)n o nh s o x a (r1)m z c n r3 r3 (i) sais farmaceuticamente aceitáveis dos mesmos, derivados deuterados de qualquer um dos expostos anteriormente e metabólitos de qualquer um dos expostos anteriormente. também são divulgadas composições farmacêuticas que compreendem os mesmos, métodos de tratamento da fibrose cística que utilizam os mesmos, e métodos para a produção dos mesmos.",VERTEX PHARMA,ALEXANDER RUSSELL ABELA;;ANDREAS TERMIN;;ANTON V GULEVICH;;BRETT B BUSCH;;BRYAN FRIEMAN;;CARL V VOGEL;;CLARA KUANG-JU HSIA;;COREY DON ANDERSON;;FABRICE PIERRE;;HARIPADA KHATUYA;;JASON MCCARTNEY;;JEREMY J CLEMENS;;JINGLAN ZHOU;;JOHNNY UY;;MARK THOMAS MILLER;;PETER GROOTENHUIS;;PING KANG;;PRASUNA PARASELLI;;SARA E SWIFT;;SARA SABINA HADIDA RUAH;;SENAIT G GHIRMAI;;THOMAS CLEVELAND;;TIMOTHY RICHARD COON;;WEICHAO GEORGE CHEN,,https://lens.org/195-432-151-155-175,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
124,US,A1,US 2019/0248809 A1,024-390-449-901-034,2019-08-15,2019,US 201916276350 A,2019-02-14,US 201916276350 A;;US 201862631453 P,2018-02-15,"Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2019-02-06);;VERTEX PHARMACEUTICALS INCORPORATED (2019-02-04),https://lens.org/024-390-449-901-034,Patent Application,yes,1,12,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/404;;A61K31/439;;A61K31/47;;A61P11/00,,0,0,,,,ACTIVE
125,PE,A1,PE 20210454 A1,160-254-861-110-984,2021-03-08,2021,PE 2020001222 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCICLOS COMO MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUISTICA, COMPOSICIONES FARMACEUTICAS DE ESTOS, SU USO EN EL TRATAMIENTO DE LA FIBROSIS QUISTICA Y PROCESOS PARA ELABORARLOS","La presente invencion se refiere a compuestos donde: el anillo A es un anillo fenilo; el anillo B es un anillo de piridinilo; el anillo D es un anillo de fenilo, un anillo de heterociclilo de 5 miembros; X es O, NH o un N (alquilo C1-C4); cada R 1 se selecciona independientemente de C 1 -C 2 grupos alquilo, C 1 -C 2 grupos alcoxilo, m es 0, 1, 2, 3 o 4; cada R 2 se selecciona independientemente de C 1 -C 2 grupos alquilo, C 1 -C 2 grupos alcoxilo, n es 0, 1 o 2; cada R 3 es metilo; cada R 4 se elige independientemente entre halogenos, un grupo oxo, un grupo hidroxilo, q es 1, 2, 3 o 4; y Z es un enlazador divalente de formula (L) r , donde: r es 1, 2, 3, 4, 5 o 6; cada L se selecciona independientemente de entre C (R 8 ) (R 9 ), grupos -O-, y -NR b - grupos, en los que un heteroatomo en Z no esta unido a otro heteroatomo en Z, en donde: cada R 8 y R 9 se seleccionan independientemente de entre hidrogeno, halogenos, C 1 - C 2 grupos haloalquilo; y cada R b se selecciona independientemente de hidrogeno y C 1 -C 2 grupos alquilo. Tambien se describen composiciones farmaceuticas que los comprenden, metodos para tratar la fibrosis quistica con ellos y metodos para prepararlos.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/160-254-861-110-984,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
126,DO,A,DO P2023000016 A,015-167-847-876-059,2023-02-28,2023,DO 2023000016 A,2023-01-27,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCICLOS COMO MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS DE ESTOS, SU USO EN EL TRATAMIENTO DE LA FIBROSIS QUÍSTICA Y PROCESOS PARA ELABORARLOS","Se revelan compuestos de la fórmula (I): (I), sus sales farmacéuticamente aceptables, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se revelan composiciones farmacéuticas que los comprenden, métodos de tratamiento de fibrosis quística que los usan y métodos para prepararlos.",VERTREX PHARMACEUTICALS INCORPORATED,PETER GROOTENHUIS;;JASON MCCARTNEY;;HARIPADA KHATUYA;;JOHNNY UY;;JINGLAN ZHOU;;ALEXANDER RUSELL ABELA;;JEREMY J CLEMENS;;COREY DON ANDERSON;;SENAIT G GHIRMAI;;PING KAN;;SARA E SWIFT;;SARA SABINA HADIDA RUAH;;CLARA KUANG-JU HSIA;;THOMAS CLEVELAND;;BRETT B BUSH;;WEICHAO GEORGE CHEN;;TIMOTHY RICHARD COON;;BRYAN FRIEMAN;;ANTON V GULEVICH;;MARK THOMAS MILLER;;PRASUNA PARASELLI;;FABRICE PIERRE;;ANDREAS TERMIN;;CARL V VOGEL,,https://lens.org/015-167-847-876-059,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,A61K31/437;;A61P11/00;;C07D513/22;;C07D515/22,,0,0,,,,PENDING
127,CL,A1,CL 2020002055 A1,073-241-327-547-290,2021-03-19,2021,CL 2020002055 A,2020-08-07,US 201862631453 P,2018-02-15,"Macrociclos como moduladores del regulador de conductncia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos.","Se revelan compuestos de la fórmula (I); sus sales farmacéuticamente aceptables, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se revelan composiciones farmacéuticas que los comprenden, métodos de tratamiento de fibrosis quística que los usan y métodos para prepararlos.",VERTEX PHARMA,MILLER MARK THOMAS;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;KHATUYA HARIPADA;;MCCARTNEY JASON;;UY JOHNNY;;ZHOU JINGLAN;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ABELA ALEXANDER RUSSELL;;PARASELLI PRASUNA;;KANG PING;;CHEN WEICHAO GEORGE;;ANDERSON COREY DON;;BUSCH BRETT B;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GULEVICH ANTON V;;HSIA CLARA KUANG-JU;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;VOGEL CARL V,,https://lens.org/073-241-327-547-290,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,A61K31/437;;A61P11/00;;C07D513/22;;C07D515/22,,0,0,,,,PENDING
128,UA,C2,UA 126304 C2,145-633-853-764-909,2022-09-14,2022,UA A202005844 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. (I),",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/145-633-853-764-909,Limited Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,,,0,0,,,,ACTIVE
129,CA,A1,CA 3088577 A1,016-890-474-398-849,2019-08-22,2019,CA 3088577 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/016-890-474-398-849,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
130,US,B2,US 11066417 B2,159-855-188-958-78X,2021-07-20,2021,US 201916276350 A,2019-02-14,US 201916276350 A;;US 201862631453 P,2018-02-15,"Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2019-02-06);;VERTEX PHARMACEUTICALS INCORPORATED (2019-02-04),https://lens.org/159-855-188-958-78X,Granted Patent,yes,97,5,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,A61K31/44;;A61K31/404;;A61K31/435;;A61K31/439;;A61K31/47;;A61P11/00;;C07D513/22;;C07D515/22,,5,1,021-201-815-497-277,28930490;;10.1164/rccm.201704-0717oc;;pmc5768901,"International Patent Application No. PCT/US2019/018042: International Search Report and Written Opinion, dated Apr. 17, 2019 (10 pages).;;Anonymous: “Symdeko in Cystic Fibrosis Patients”, ClinicalTrials.gov, Jul. 23, 2018 (Apr. 23, 2004), XP055661778, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/record/NCT03506061 [retrieved on Jan. 24, 2020].;;Donaldson, S.H. et al. (2017) “Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR”, Am. J. Respir. Crit. Care Med., 197(2): 214-224.;;International Patent Application No. PCT/US2019/061171: International Search Report and Written Opinion, dated Feb. 2, 2020 (14 pages).;;International Patent Application No. PCT/U2020/026331: International Search Report and Written Opinion, dated May 29, 2020 (14 pages).",ACTIVE
131,MA,B1,MA 51828 B1,010-301-600-653-796,2022-11-30,2022,MA 51828 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé","L'invention concerne des composés de formule (i), des sels pharmaceutiquement acceptables de ceux-ci, des dérivés deutérés et des métabolites de l'un quelconque des précédents. L'invention concerne également des compositions pharmaceutiques les comprenant, des méthodes de traitement de la fibrose kystique à l'aide de celles-ci, et des procédés de fabrication de celles-ci.",VERTEX PHARMA,ZHOU JINGLAN;;MILLER MARK THOMAS;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;KHATUYA HARIPADA;;MCCARTNEY JASON;;UY JOHNNY;;GROOTENHUIS PETER;;KANG PING;;PARASELLI PRASUNA;;CHEN WEICHAO GEORGE;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;VOGEL CARL V,,https://lens.org/010-301-600-653-796,Granted Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,A61K31/437;;A61P11/00;;C07D513/22;;C07D515/22,,0,0,,,,ACTIVE
132,TW,A,TW 202304937 A,030-719-583-420-440,2023-02-01,2023,TW 111138279 A,2019-02-15,US 201862631453 P,2018-02-15,"Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/030-719-583-420-440,Patent of Addition,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/4375;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
133,DK,T3,DK 3752510 T3,058-968-136-682-629,2023-01-16,2023,DK 19707648 T,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MAKROCYKLUSSER SOM MODULATORER AF CYSTISK FIBROSE TRANSMEMBRANKONDUKTANSREGULATOR, FARMACEUTISKE SAMMENSÆTNINGER DERAF, DERES ANVENDELSE I BEHANDLINGEN AF CYSTISK FIBROSE OG FREMGANGSMÅDE TIL FREMSTILLING DERAF",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/058-968-136-682-629,Granted Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,ACTIVE
134,EP,A1,EP 3752510 A1,094-566-234-581-294,2020-12-23,2020,EP 19707648 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/094-566-234-581-294,Patent Application,yes,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,ACTIVE
135,AU,B2,AU 2019/222758 B2,007-232-712-743-775,2022-07-07,2022,AU 2019/222758 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/007-232-712-743-775,Granted Patent,no,4,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,ACTIVE
136,RS,B1,RS 64018 B1,056-653-488-051-768,2023-03-31,2023,RS P20230079 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W;;EP 19707648 A,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/056-653-488-051-768,Granted Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,ACTIVE
137,MX,A,MX 2020008268 A,074-942-289-152-033,2020-09-21,2020,MX 2020008268 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM.","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,BUSCH BRETT B;;MILLER MARK THOMAS;;ZHOU JINGLAN;;MCCARTNEY JASON;;PARASELLI PRASUNA;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;KHATUYA HARIPADA;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ABELA ALEXANDER RUSSELL;;HSIA CLARA KUANG-JU;;KANG PING;;UY JOHNNY;;CHEN WEICHAO GEORGE;;ANDERSON COREY DON;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GULEVICH ANTON V;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;VOGEL CARL V,,https://lens.org/074-942-289-152-033,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
138,US,B2,US 11866450 B2,012-491-640-725-988,2024-01-09,2024,US 202117323267 A,2021-05-18,US 202117323267 A;;US 201916276350 A;;US 201862631453 P,2018-02-15,"Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2019-02-06);;VERTEX PHARMACEUTICALS INCORPORATED (2019-02-04),https://lens.org/012-491-640-725-988,Granted Patent,yes,145,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/404;;A61K31/439;;A61K31/47;;A61P11/00;;C07D515/22,,48,25,093-386-739-810-81X;;096-979-652-416-855;;023-526-186-270-579;;043-882-821-564-688;;040-089-442-352-13X;;013-937-078-602-349;;108-992-903-319-970;;008-288-483-975-079;;064-283-996-955-602;;036-217-822-811-595;;024-098-611-439-477;;026-889-919-284-583;;085-090-972-352-410;;123-679-085-350-740;;078-500-003-147-683;;103-406-692-390-577;;007-439-541-841-087;;075-656-809-634-642;;070-656-490-730-816;;051-392-666-499-166;;045-117-341-960-248;;105-058-797-596-365;;012-280-371-916-857;;006-044-365-742-596;;021-201-815-497-277,10.31525/ct1-nct03911713;;10.31525/ct1-nct03912233;;14180597;;5542665;;10.1021/op000018u;;23394148;;10.1021/ol400049m;;10.1021/ja01204a044;;18919711;;25431015;;10.1111/cbdd.12486;;10.1002/ejoc.201801270;;10.1128/aac.40.3.727;;pmc163188;;8851601;;19108116;;pmc1509782;;10.1111/j.1476-5381.1947.tb00331.x;;20258350;;28427017;;10.1016/j.ejmech.2017.04.028;;10.1016/s0040-4020(03)01206-7;;10.1080/00397910008087410;;10.1002/anie.201800699;;29424956;;pmc5937270;;10.1021/jo01329a020;;28483454;;10.1016/j.bmc.2017.04.034;;10.1021/acs.jmedchem.6b01889;;28418664;;10.1021/acs.jmedchem.6b01889.s001;;10.1021/ja01262a034;;8627606;;10.1021/jm9508651;;21022267;;10.1039/jr9460000081;;10.1021/ja01847a063;;10.1021/ja01856a046;;10.1248/yakushi1947.70.3_126;;28930490;;10.1164/rccm.201704-0717oc;;pmc5768901,"“A Phase 1/2 Study of VX-121 in Healthy Subjects and in Subjects with Cystic Fibrosis,” EU Clinical Trials Register, May 3, 2019 (May 3, 2019), XP055903414, Retrieved from the Internet: URL:https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000126-55/NL [retrieved on Mar. 21, 2022].;;“A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis,” ClinicatTials.gov, Apr. 11, 2019 (Apr. 11, 2019), XP055903562, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NCT03911713 [retrieved on Mar. 21, 2022].;;“A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects with Cystic Fibrosis,” ClinicalTrials.gov, Apr. 30, 2019 (Apr. 30, 2019), XP55903330, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NCT03912233 [retrieved on Mar. 21, 2022].;;Alberti, C. and Tironi, C. (1964), “Sulfanilammidi Pirazoliche,” VI. 1-(Tolil)-sulfanilamidopirazoli derivati dal 3-aminopirazolo, dal 4-aminopirazolo e dal 3-metil-5-aminopirazolo, II Farmaco—Ed. Sc. 29(7), 618-637.;;Alberti, C. and Tironi, C. (1971), “Sulfanilammidi Pirazoliche,” II Farmaco—Ed. Sc. 26(1), 66-88.;;Bastin, Richard J., et al., “Salt selection and optimization procedures for pharmaceutical new chemical entities,” Org. Pro. Res. Dev. 2000, 4(5), 427-435.;;Borhade, Sanjay R., et al., “Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor,” Organic Letters, 2013, vol. 15, No. 5, pp. 1056-1059, XP055374206A, © 2013 American Chemical Society, ISSN: 1523-7060, DOI:10.1021/ol4/00049m, published on web Feb. 13, 2013.;;Braker, William, et al. (1947), “Substituted Sulfanilamidopyrimidines,” J. Am. Chem. Society, 69, 3072-3078.;;Chen, Liangzhu, et al. (2014), “Synthesis and Antimicrobial Activity of the Hybrid Molecules between Sulfonamides and Active Antimicrobial Pleuromutilin Derivative,” Chemical Biology and Drug Design, 86(2), 239-245.;;Cherepakha, Artem Yu., et al. (2018), “Hetaryl Bromides Bearing the SO2F Group—Versatile Substrates for Palladium-Catalyzed C-C Coupling Reactions,” Eur J Org Chem, 47: 6682-6692.;;Chio, Li-Chun, et al. (1996), “Identification of a Class of Sulfonamides Highly Active Against Dihydropteroate Synthase from Toxoplasma Gondii, Pneumocystis Carinii, and Mycobacterium Avium,” Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 40(3), 727-733.;;Gage, J. C., et al. (1947), “2-P-Aminobenzenesulphonamido-4 : 6-Dimethoxypyrimidine: Experimental Evaluation,” British Journal of Pharmacology and Chemotherapy, 2(3), 149-162.;;Ghorab, Mostafa M. et al., (2017), “Aromatase inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and molecular modeling studies of novel phenothiazine derivatives carrying sulfonamide moiety as hybrid molecules,” Eur. J. Med. Chem., 134, 304-315.;;Gomes, Paula, et al. (2003), “Amino acids as selective sulfonamide acylating agents,” Tetrahedron, 59(38), 7473-7480.;;Hassan, Hammed H. A. and Soliman, R. (2000), “Synthesis and GC-EIMS Analyses of Optically Pure 3-Hydroxy-2-azetidinones Having N-sulfonamide Drugs Side Chain,” Synthetic Communications, 30(14), 2465-2478.;;International Patent Application No. PCT/US2021/053853: International Search Report and Written Opinion, dated Dec. 21, 2021 (12 pages).;;International Patent Application No. PCT/US2021/053855: International Search Report and Written Opinion, dated Jan. 3, 2022 (12 pages).;;International Patent Application No. PCT/US2021/053856: International Search Report and Written Opinion, dated Dec. 22, 2021 (12 pages).;;International Patent Application No. PCT/US2021/053858: International Search Report and Written Opinion, dated Mar. 17, 2022 (14 pages).;;International Patent Application No. PCT/US2021/053860: International Search Report and Written Opinion, dated Dec. 23, 2021 (12 pages).;;International Patent Application No. PCT/US2021/053861: International Search Report and Written Opinion, dated Dec. 22, 2021 (12 pages).;;International Patent Application No. PCT/US2021/053862: International Search Report and Written Opinion, dated Dec. 22, 2021 (12 pages).;;International Patent Application No. PCT/US2021/053863: International Search Report and Written Opinion, dated Feb. 4, 2022 (16 pages).;;International Patent Application No. PCT/US2021/053864: International Search Report and Written Opinion, dated Mar. 15, 2022 (17 pages).;;International Patent Application No. PCT/US2021/053865: International Search Report and Written Opinion, dated Jan. 26, 2022 (16 pages).;;International Patent Application No. PCT/US2021/062687: International Search Report and Written Opinion, dated Apr. 4, 2022 (16 pages).;;Kim, Taehoon, et al. (2018), “Sulfonamidation of Aryl and Heteroaryl Halides through Photosensitized Nickel Catalysis,” Agewandte Chemie, 57, 3488-3492.;;Newkome, George R., et al. (1979), “Nicotinic Acid Crown Ethers. Synthesis, Reactions, and Complexation of Nicotinonitrile Macrocycles,” J Org Chem, 44(15): 2639-2697.;;Nishida, Haruyuki, et al. (2017), “Exploration of pyrrole derivatives to find an effective potassium competitive acid blocker with moderately long-lasting suppression of gastric acid secretion,” Bioorg Med Chem, 25(13): 3447-3460.;;Prashantha, Gunaga, et al. (2017), “Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide,” J Med Chem, 60(9): 3795-3803.;;Raiziss, George W., et al. (1942), “N1-Sulfanilylaminoalkylpyrimidines,” J. Am. Chem. Soc. 64, 2340-2342.;;Rewcastle, Gordon W., et al. (1996), “Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-Bromophenyl)amino]pyrido[d]-pyrimidines Are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor,” J Med Chem, 39(9): 1823-1835.;;Rose, F. L., et al. (1946), “P-Aminobenzenesulphonamide Derivatives of Pyrimidines as Antibacterial Agents,” J. Am. Chem. Soc., 81-85.;;Sprague, James M., et al. (1941), “Sulfonamido derivatives of thiazoles,” J. Am. Chem. Soc. 63, 578-580.;;Sprague, James M., et al. (1941), “Sulfonamido derivatives of pyrimidines,” J. Am. Chem. Soc. 63, 3028-3030.;;Sugasawa, Shigehiko, et al. (1949), “Reaction between sulfaguanidine and 1,3-keto aldehydes. I. Synthesis of 2-sulfanilamido-4-methylpyrimidine,” 69, 82-85.;;Tani, Chiaki, et al. (1950), “Syntheses of sulfanilamide derivatives containing diphenylene oxide,” Journal of the Pharmaceutical Society of Japan, 70, 126-127.;;U.S. Appl. No. 16/992,419, filed Aug. 13, 2021, by Angell et al.;;U.S. Appl. No. 16/992,441, filed Aug. 13, 2021, by Shi et al.;;U.S. Appl. No. 16/992,448, filed Aug. 13, 2021, by Anderson et al.;;U.S. Appl. No. 16/992,675, filed Aug. 13, 2021, by Abela et al.;;U.S. Appl. No. 17/546,649, filed Dec. 9, 2021, by Borek et al.;;U.S. Appl. No. 17/600,829, filed Oct. 1, 2021, by Abela et al.;;Anonymous: “Symdeko in Cystic Fibrosis Patients”, CiinicalTriais.gov, Jul. 23, 2018 (Apr. 23, 2018). XP055661778, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/record/NCT03506061 (retrieved on Jan. 24, 2020).;;Donaldson. S.H. et al. (201 7) “Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR”, Am. J. Respir. Crit. Care Med., 197(2): 214-224.;;International Patent Application No. PCT/US2019/018042: international Search Report and Written Opinion, dated Apr. 17, 2019 (10 pages).;;International Patent Application No. PCT/US2019/061171: International Search Report and Written Opinion, dated Feb. 2, 2020 (14 pages).;;International Patent Application No. PCT/U2020/026331: International Search Report and Written Opinion, dated May 29, 2020 (14 pages).",ACTIVE
139,AU,A1,AU 2022/231721 A1,016-429-317-469-302,2022-10-06,2022,AU 2022/231721 A,2022-09-15,AU 2022/231721 A;;AU 2019/222758 A;;US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYSTIC FIBROSIS, AND PROCESS FOR MAKING THEM","Compounds of Formula (I): (R2 n2 N/ R1)m (R4)q R3 pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,CLEMENS JEREMY J;;ANDERSON COREY DON;;BUSCH BRETT B;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;CHEN WEICHAO GEORGE;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL,,https://lens.org/016-429-317-469-302,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
140,CR,A,CR 20200403 A,134-078-770-838-82X,2020-10-26,2020,CR 20200403 A,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM","<p>Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.</p>",VERTEX PHARMA,UY JOHNNY;;PARASELLI PRASUNA;;HSIA CLARA KUANG-JU;;CLEMENS JEREMY J;;CHEN WEICHAO GEORGE;;MCCARTNEY JASON;;MILLER MARK THOMAS;;ANDERSON COREY DON;;FRIEMAN BRYAN;;PIERRE FABRICE;;GULEVICH ANTON V;;TERMIN ANDREAS;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;KANG PING;;SWIFT SARA E;;VOGEL CARL V;;HADIDA RUAH SARA SABINA;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT B;;KHATUYA HARIPADA;;ZHOU JINGLAN,,https://lens.org/134-078-770-838-82X,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D515/22;;A61K31/437;;A61P11/00;;C07D513/22,,0,0,,,,PENDING
141,CN,A,CN 117285547 A,142-847-160-537-521,2023-12-26,2023,CN 202310999824 A,2019-02-14,US 201862631453 P;;CN 201980025942 A;;US 2019/0018042 W,2018-02-15,"Macrocyclic compounds as modulators of CFTR, pharmaceutical compositions thereof, their use and processes for their preparation","The present disclosure relates to macrocyclic compounds that are modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and methods for their preparation. In particular, the present application discloses a compound of Formula (I), a pharmaceutically acceptable salt thereof, a deuterated derivative of any of the foregoing, and a metabolite of any of the foregoing. Also disclosed are pharmaceutical compositions comprising the above, methods of treating cystic fibrosis using the above, and methods for preparing the above. # imgabs0 #",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON CHRISTOPHER D;;BUSH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FREEMAN BRYAN;;GILMER STEPHEN G;;GROOTENHUIS PETER;;GUREVICH ALEKSANDR VLADIMIROVICH;;HADIDA RUAH SARA SABINA;;HSIA CHIH KUANG-JEN;;KANG PENGJU;;KHATUYA HARISH;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;CHOU JOEY,,https://lens.org/142-847-160-537-521,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/404;;A61K31/439;;A61K31/47;;A61P11/00;;C07D405/12;;C07D515/22,,0,0,,,,PENDING
142,UY,A,UY 38093 A,163-185-936-853-17X,2019-10-01,2019,UY 38093 A,2019-02-15,US 201862631453 P,2018-02-15,"MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANA DE FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS, MÉTODOS DE TRATAMIENTO Y PROCESO DE PREPARACIÓN DE LOS MODULADORES","Se revelan compuestos de la fórmula (I): sus sales farmacéuticamente aceptables, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se revelan composiciones farmacéuticas que los comprenden, métodos de tratamiento de fibrosis quística usando los mismos y métodos para prepararlos.",VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/163-185-936-853-17X,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,A61P11/00;;A61K31/4353;;A61K31/4365;;A61K31/437;;A61K31/4375;;C07D513/14;;C07D513/22;;C07D515/22,,0,0,,,,PENDING
143,HR,T1,HR P20230030 T1,177-068-701-114-01X,2023-03-03,2023,HR P20230030 T,2019-02-14,US 201862631453 P;;EP 19707648 A;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CLEVELAND THOMAS;;CHEN WEICHAO GEORGE;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/177-068-701-114-01X,Granted Patent,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,ACTIVE
144,PL,T3,PL 3752510 T3,174-392-934-357-691,2023-05-08,2023,PL 19707648 T,2019-02-14,US 201862631453 P;;US 2019/0018042 W,2018-02-15,"MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM",,VERTEX PHARMA,CLEMENS JEREMY J;;ABELA ALEXANDER RUSSELL;;ANDERSON COREY DON;;BUSCH BRETT B;;CHEN WEICHAO GEORGE;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;KANG PING;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;UY JOHNNY;;VOGEL CARL V;;ZHOU JINGLAN,,https://lens.org/174-392-934-357-691,Patent Application,no,0,0,54,54,0,C07D515/22;;A61K31/47;;A61K31/404;;A61K31/439;;A61P11/00;;C07D513/22;;C07D513/22;;A61P11/00;;A61K31/439;;C07D515/22;;C07D513/18;;C07D515/18;;A61K31/437;;A61K31/4375;;C07D513/22;;C07D515/22;;A61K31/439;;A61K31/404;;A61K31/47;;A61P11/00;;A61P43/00;;C07D513/22;;A61K31/439;;A61P11/00;;A61K31/47;;A61K31/404;;C07D515/22,C07D513/22;;A61K31/437;;A61P11/00;;C07D515/22,,0,0,,,,PENDING
145,MX,A,MX 2022001827 A,186-580-350-464-956,2022-06-09,2022,MX 2022001827 A,2020-08-13,US 201962886739 P;;US 201962886611 P;;US 2020/0046122 W,2019-08-14,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR.,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.",VERTEX PHARMA,BUSCH BRETT B;;MILLER MARK THOMAS;;ZHOU JINGLAN;;MCCARTNEY JASON;;PARASELLI PRASUNA;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;KHATUYA HARIPADA;;HADIDA RUAH SARA SABINA;;ABELA ALEXANDER RUSSELL;;UY JOHNNY;;ANDERSON COREY DON;;FRIEMAN BRYAN;;GHIRMAI SENAIT G;;PIERRE FABRICE;;SWIFT SARA E;;TERMIN ANDREAS;;VOGEL CARL V;;GROOTENHUIS (FALLECIDO) PETER;;BOOKSER BRETT C;;GULEVICH ANTON V;;ISHIHARA YOSHIHIRO,,https://lens.org/186-580-350-464-956,Patent Application,no,0,0,13,13,0,C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61P11/00;;C07D513/22;;A61K31/435;;A61K31/403;;A61K31/47;;A61K45/06;;A61P11/00;;A61K31/404;;A61K31/439;;A61K31/4418;;A61K31/47;;A61K31/529;;C07D513/22,A61P11/00;;A61K31/435;;C07D513/22,,0,0,,,,PENDING
146,KR,A,KR 20230104618 A,124-026-070-893-10X,2023-07-10,2023,KR 20237015298 A,2021-10-06,US 202063088935 P;;US 2021/0053860 W,2020-10-07,낭성 섬유증 막관통 전도도 조절자의 조절제,본 개시는 코어 구조를 갖는 낭포성 섬유증 막관통 전도도 조절자(CFTR)의 조절제: JPEGpct00625.jpg4878 적어도 하나의 이러한 조절제를 함유하는 약학적 조성물; 이러한 조절제 및 약학적 조성물을 사용해 낭성 섬유증을 포함하는 CFTR 매개 질환을 치료하는 방법; 병용 약학적 조성물 및 병용 요법; 및 이러한 조절제를 제조하기 위한 프로세스 및 중간체를 제공한다.,VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/124-026-070-893-10X,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
147,BR,A2,BR 112023006381 A2,194-116-004-132-861,2023-09-26,2023,BR 112023006381 A,2021-10-06,US 2021/0053860 W;;US 202063088935 P,2020-10-07,Moduladores de regulador de condutância transmembrana de fibrose cística,"moduladores de regulador de condutância transmembrana de fibrose cística. esta divulgação fornece moduladores do regulador de condutância transmembrana de fibrose cística (cftr) com a estrutura nuclear: composições farmacêuticas contendo pelo menos um referido modulador, métodos de tratamento de doenças mediadas por cftr, incluindo fibrose cística, usando os referidos moduladores e composições farmacêuticas, composições farmacêuticas de combinação e terapias de combinação, e processos e intermediários para produzir os referidos moduladores.",VERTEX PHARMA,ALEXANDER RUSSELL ABELA;;SILINA ALINA;;ANTON V GULEVICH;;BRYAN A FRIEMAN;;COREY DON ANDERSON;;PIERRE FABRICE;;KHATUYA HARIPADA;;CHAU JACLYN;;MCCARTNEY JASON;;CLEMENS JEREMY;;ZHOU JINGLAN;;JOE A TRAN;;UY JOHNNY;;LEV TYLER DEWEY FANNING;;VALDEZ LINO;;MARK THOMAS MILLER;;KRENITSKY PAUL;;GROOTENHUIS PETER;;PARASELLI PRASUNA;;SARA SABINA HADIDA RUAH;;ABRAHAM SUNNY;;CLEVELAND THOMAS;;TIMOTHY A DWIGHT;;TIMOTHY RICHARD COON;;ARUMUGAM VIJAYALAKSMI;;MELILLO VITO;;ISHIHARA YOSHIHIRO,,https://lens.org/194-116-004-132-861,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
148,EC,A,EC SP23032164 A,061-148-895-459-545,2023-06-30,2023,EC DI202332164 A,2023-05-02,US 202063088935 P,2020-10-07,MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura central: composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas combinadas y terapias combinadas, y procesos y productos intermediarios para la fabricación de tales moduladores.",VERTEX PHARMA,CLEVELAND THOMAS;;ZHOU JINGLAN;;KHATUYA HARIPADA;;MILLER MARK THOMAS;;MCCARTNEY JASON;;ABRAHAM SUNNY;;PARASELLI PRASUNA;;HADIDA RUAH SARA SABINA;;GULEVICH ANTON V;;ABELA ALEXANDER RUSSELL;;TRAN JOE;;ISHIHARA YOSHIHIRO;;CLEMENS JEREMY;;DWIGHT TIMOTHY A;;CHAU JACLYN;;PIERRE FABRICE;;MELILLO VITO;;FANNING LEV TYLER DEWEY;;GROOTENHUIS PETER (FALLECIDO);;SILINA ALINA;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;KRENITSKY PAUL;;FRIEMAN BRYAN A;;UY JOHNNY;;VALDEZ LINO;;COON TIMOTHY RICHARD,,https://lens.org/061-148-895-459-545,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
149,CN,A,CN 116783204 A,020-487-093-653-978,2023-09-19,2023,CN 202180081900 A,2021-10-06,US 202063088935 P;;US 2021/0053860 W,2020-10-07,Modulators of cystic fibrosis transmembrane conductance regulators,"The present disclosure provides modulators of cystic fibrosis transmembrane conductance regulatory factor (CFTR), the modulators having a core structure: pharmaceutical compositions containing at least one such modulator; methods of treating CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions; a combination pharmaceutical composition and a combination therapy; and processes and intermediates for preparing such modulators. # imgabs0 #",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM STEFFEN;;ANDERSON CHRISTOPHER D;;ARUMUGAM VIDYA;;CHOU JOEY;;CLEMENS JOHN;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TERRY A;;FANNING LEV T D;;FREEMAN BRYAN A;;GROOTENHUIS PETER;;GUREVICH ALEKSANDR VLADIMIROVICH;;HADIDA RUAH SARA SABINA;;ISHIHARA YASUO;;KHATUYA HARDIK;;KRENITZKY PAVEL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LUIS;;CHOU JOEY,,https://lens.org/020-487-093-653-978,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/08;;A61K31/529;;A61P1/00;;A61P1/18;;A61P11/00;;A61P43/00,,0,0,,,,PENDING
150,CR,A,CR 20230200 A,051-574-196-278-381,2023-07-13,2023,CR 20230200 A,2021-10-06,US 202063088935 P;;US 2021/0053860 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura central: composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas combinadas y terapias combinadas, y procesos y productos intermediarios para la fabricación de tales moduladores.",VERTEX PHARMA,ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;DWIGHT TIMOTHY A;;GULEVICH ANTON V;;CHAU JACLYN;;HADIDA RUAH SARA SABINA;;MELILLO VITO;;CLEMENS JEREMY;;KRENITSKY PAUL;;VALDEZ LINO;;ZHOU JINGLAN;;MCCARTNEY JASON;;PARASELLI PRASUNA;;CLEVELAND THOMAS;;MILLER MARK THOMAS;;GROOTENHUIS PETER;;ABELA ALEXANDER RUSSELL;;TRAN JOE A;;KHATUYA HARIPADA;;FRIEMAN BRYAN A;;ISHIHARA YOSHIHIRO;;SILINA ALINA;;UY JOHNNY;;FANNING LEV TYLER DEWEY;;COON TIMOTHY RICHARD;;PIERRE FABRICE,,https://lens.org/051-574-196-278-381,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,,,0,0,,,,PENDING
151,PE,A1,PE 20231185 A1,075-076-382-605-496,2023-08-11,2023,PE 2023001369 A,2021-10-06,US 202063088935 P;;US 2021/0053860 W,2020-10-07,MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUISTICA,"REFERIDO A COMPUESTOS MACROLIDOS DE FORMULA (I) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN DONDE LOS ANILLOS A Y B, W1, W2, Z, L1, L2, R3, R4, R5 Y RYN SON TAL COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: (11R)-6-[2-(HIDROXIMETIL)-6-METIL-FENIL]-11-ISOBUTIL-2,2-DIOXO-12-ESPIRO[2.3]HEXAN-5-IL-9-OXA-2 LAMDA 6-TIA-3,5,12,19-TETRAZATRICICLO[12.3.1.14,8]NONADECA-1(18),4(19),5,7,14,16-HEXAEN-13-ONA; (11R)-6-(2,6-DIMETILFENIL)-11-ISOPENTIL-12-[1-(2-METOXIETIL)PIRAZOL-4-IL]-2,2-DIOXO-9-OXA-2 LAMDA 6-TIA-3,5,12,19-TETRAZATRICICLO[12.3.1.14,8]NONADECA-1(18),4(19),5,7,14,16-HEXAEN-13-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS. DICHOS COMPUESTOS SON MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUISTICA (CFTR) SIENDO UTILES EN EL TRATAMIENTO DE FIBROSIS QUISTICA.",VERTEX PHARMA,FRIEMAN BRYAN A;;MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/075-076-382-605-496,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
152,US,A1,US 2023/0382925 A1,081-765-126-660-075,2023-11-30,2023,US 202118030529 A,2021-10-06,US 202118030529 A;;US 202063088935 P;;US 2021/0053860 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS SAN DIEGO (2002-10-22);;VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2021-09-28);;VERTEX PHARMACEUTICALS INCORPORATED (2021-09-21),https://lens.org/081-765-126-660-075,Patent Application,yes,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/08;;A61K45/06,,0,0,,,,PENDING
153,WO,A1,WO 2022/076624 A1,113-376-748-293-572,2022-04-14,2022,US 2021/0053860 W,2021-10-06,US 202063088935 P,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER (DECEASED);;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/113-376-748-293-572,Patent Application,yes,32,4,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/04;;A61K31/519;;A61P43/00,,11,7,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;139-606-967-003-103;;009-491-011-950-586;;007-364-858-655-289,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1002/jps.2600660104;;833720,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, 1990, pages 863 - 870;;KEREM, B-S ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;FASEB J, vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50;;WUTS, P. G. M.: ""Greene's Protective Groups in Organic Synthesis: Fifth Edition"", 2014, JOHN WILEY AND SONS;;LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;REMINGTON: ""Encyclopedia of Pharmaceutical Technology"", 1988, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA",PENDING
154,EP,A1,EP 4225764 A1,039-807-432-000-518,2023-08-16,2023,EP 21814947 A,2021-10-06,US 202063088935 P;;US 2021/0053860 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/039-807-432-000-518,Patent Application,yes,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
155,AU,A1,AU 2021/358063 A1,166-008-844-363-95X,2023-05-18,2023,AU 2021/358063 A,2021-10-06,US 202063088935 P;;US 2021/0053860 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER (DECEASED);;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/166-008-844-363-95X,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
156,AU,A1,AU 2021/358512 A1,053-779-023-616-858,2023-05-18,2023,AU 2021/358512 A,2021-10-06,US 202063088686 P;;US 2021/0053858 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;VICKERS TROY;;ZHOU JINGLAN,,https://lens.org/053-779-023-616-858,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
157,TW,A,TW 202233635 A,105-829-384-637-619,2022-09-01,2022,TW 110137149 A,2021-10-06,US 202063088935 P,2020-10-07,Modulators of Cystic Fibrosis Transmembrane Conductance Regulator,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/105-829-384-637-619,Patent of Addition,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
158,CL,A1,CL 2023000984 A1,184-006-292-786-105,2023-11-24,2023,CL 2023000984 A,2023-04-05,US 202063088935 P,2020-10-07,Moduladores del regulador de la conductancia transmembrana de la fibrosis quística,"Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura central: composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas combinadas y terapias combinadas, y procesos y productos intermediarios para la fabricación de tales moduladores.",VERTEX PHARMA,THOMAS CLEVELAND;;PETER GROOTENHUIS;;SARA SABINA HADIDA RUAH;;VITO MELILLO;;MARK THOMAS MILLER;;PRASUNA PARASELLI;;LINO VALDEZ;;JINGLAN ZHOU;;JASON MCCARTNEY;;ALEXANDER RUSSELL ABELA;;SUNNY ABRAHAM;;COREY DON ANDERSON;;VIJAYALAKSMI ARUMUGAM;;JACLYN CHAU;;JEREMY CLEMENS;;TIMOTHY RICHARD COON;;TIMOTHY A DWIGHT;;LEV TYLER DEWEY FANNING;;BRYAN A FRIEMAN;;ANTON V GULEVICH;;YOSHIHIRO ISHIHARA;;HARIPADA KHATUYA;;PAUL KRENITSKY;;FABRICE PIERRE;;ALINA SILINA;;JOE A TRAN;;JOHNNY UY,,https://lens.org/184-006-292-786-105,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,A61K31/519;;A61P43/00;;C07D515/04,,0,0,,,,PENDING
159,DO,A,DO P2023000066 A,129-700-726-169-039,2023-07-09,2023,DO 2023000066 A,2023-04-05,US 202063088935 P;;US 2021/0053860 W,2020-10-07,MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura central: composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas combinadas y terapias combinadas, y procesos y productos intermediarios para la fabricación de tales moduladores.",VERTEX PHARMA,JASON MCCARTNEY;;MARK THOMAS MILLER;;THOMAS CLEVELAND;;BRYAN A FRIEMAN;;HARIPADA KHATUYA;;JOHNNY UY;;JINGLAN ZHOU;;ALEXANDER RUSSELL ABELA;;TIMOTHY RICHARD COON;;JACLYN CHAU;;JEREMY CLEMENS;;TIMOTHY A DWIGHT;;SARA SABINA HADIDA RUAH;;PAUL KRENITSKY;;VITO MELILLO;;PRASUNA PARASELLI;;FABRICE PIERRE;;SUNNY ABRAHAM;;COREY DON ANDERSON;;VIJAYALASKSMI ARUMUGAM;;LEV TYLER DEWEY FANNING;;PETER GROOTENHUIS (FALLECIDO);;YOSHIHIRO ISHIHARA;;ALINA SILINA;;JOE A TRAN;;LINO VALDEZ;;ANTON V GULEVICH,,https://lens.org/129-700-726-169-039,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,A61K31/519;;A61P43/00;;C07D515/04,,0,0,,,,PENDING
160,CA,A1,CA 3197857 A1,145-209-914-003-458,2022-04-14,2022,CA 3197857 A,2021-10-06,US 202063088935 P;;US 2021/0053860 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;ZHOU JINGLAN;;GROOTENHUIS PETER,,https://lens.org/145-209-914-003-458,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,A61K31/519;;A61P43/00;;C07D515/04,,0,0,,,,PENDING
161,AR,A1,AR 123709 A1,196-353-000-142-984,2023-01-04,2023,AR P210102779 A,2021-10-07,US 202063088935 P,2020-10-07,MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANARIO DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores.",VERTEX PHARMA,MCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAN VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER FALLECIDO;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;ZHOU JINGLAN,,https://lens.org/196-353-000-142-984,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
162,UY,A,UY 39460 A,179-712-677-804-367,2022-05-31,2022,UY 39460 A,2021-10-07,US 202063088935 P,2020-10-07,MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANARIO DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores",VERTEX PHARMA,GROOTENHUIS PETER;;SARA SABINA HADIDA RUAH;;CLEVELAND THOMAS;;BRYAN A FRIEMAN;;KHATUYA HARIPADA;;MELILLO VITO;;ZHOU JINGLAN;;ALEXANDER RUSSELL ABELA;;MARK THOMAS MILLER;;UY JOHNNY;;MCCARTNEY JASON;;ABRAHAM SUNNY;;COREY DON ANDERSON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;TIMOTHY A DWIGHT;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;PIERRE FABRICE;;SILINA ALINA;;TIMOTHY RICHARD COON;;LEV TYLER DEWEY FANNING;;ANTON V GULEVICH;;JOE A TRAN;;VALDEZ LINO;;PARASELLI PRASUNA,,https://lens.org/179-712-677-804-367,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,A61K31/36;;A61K31/404;;A61K31/443;;A61K31/47;;A61K31/519;;A61P11/00;;C07D515/04,,0,0,,,,PENDING
163,EC,A,EC SP23032843 A,006-974-285-519-897,2023-06-30,2023,EC DI202332843 A,2023-05-04,US 202063088686 P,2020-10-07,MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUÍSTICA,"La descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura principal (I), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de enfermedades mediadas por CFTR, incluida la fibrosis quística, que usan tales moduladores y composiciones farmacéuticas, combinación de composiciones farmacéuticas y terapias combinadas que emplean estos moduladores y procesos de fabricación de tales moduladores.",VERTEX PHARMA,UY JOHNNY;;GROOTENHUIS PETER (FALLECIDO);;GULEVICH ANTON V;;VICKERS TROY;;FRIEMAN BRYAN A;;COON TIMOTHY RICHARD;;SILINA ALINA;;CHAU JACLYN;;VALDEZ LINO;;MILLER MARK THOMAS;;KRENITSKY PAUL;;ARUMUGAM VIJAYALAKSMI;;DWIGHT TIMOTHY A;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;PIERRE FABRICE;;CLEVELAND THOMAS;;ANDERSON COREY DON;;MELILLO VITO;;MCCARTNEY JASON;;ISHIHARA YOSHIHIRO;;TRAN JOE;;FANNING LEV TYLER DEWEY;;KHATUYA HARIPADA;;ZHOU JINGLAN;;PARASELLI PRASUNA;;CLEMENS JEREMY;;HADIDA RUAH SARA SABINA,,https://lens.org/006-974-285-519-897,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18,,0,0,,,,PENDING
164,CO,A2,CO 2023005734 A2,040-002-259-915-198,2023-07-21,2023,CO 2023005734 A,2023-05-05,US 2021/0053860 W;;US 202063088935 P,2020-10-07,Moduladores del regulador de la conductancia transmembrana de la fibrosis quística,"Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura central: composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas combinadas y terapias combinadas, y procesos y productos intermediarios para la fabricación de tales moduladores.",VERTEX PHARMA,CLEVELAND THOMAS;;PIERRE FABRICE JEAN DENIS;;ANDERSON COREY DON;;COON TIMOTHY RICHARD;;GROOTENHUIS PETER (DECEASED);;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;DWIGHT TIMOTHY A;;FRIEMAN BRYAN A;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MELILLO VITO;;SILINA ALINA;;UY JOHNNY;;FANNING LEV TYLER DEWEY;;GULEVICH ANTON V;;KHATUYA HARIPADA;;VALDEZ LINO;;TRAN JOE A,,https://lens.org/040-002-259-915-198,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
165,CL,A1,CL 2023000988 A1,110-620-207-033-498,2023-09-15,2023,CL 2023000988 A,2023-04-05,US 202063088686 P,2020-10-07,Moduladores del regulador de la conductancia transmembrana de la fibrosis quística,"La descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura principal (I), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de enfermedades mediadas por CFTR, incluida la fibrosis quística, que usan tales moduladores y composiciones farmacéuticas, combinación de composiciones farmacéuticas y terapias combinadas que emplean estos moduladores y procesos de fabricación de tales moduladores.",VERTEX PHARMA,THOMAS CLEVELAND;;PETER GROOTENHUIS;;SARA SABINA HADIDA RUAH;;VITO MELILLO;;MARK THOMAS MILLER;;PRASUNA PARASELLI;;LINO VALDEZ;;JINGLAN ZHOU;;JASON MCCARTNEY;;ALEXANDER RUSSELL ABELA;;SUNNY ABRAHAM;;COREY DON ANDERSON;;VIJAYALAKSMI ARUMUGAM;;JACLYN CHAU;;JEREMY CLEMENS;;TIMOTHY RICHARD COON;;TIMOTHY A DWIGHT;;LEV TYLER DEWEY FANNING;;BRYAN A FRIEMAN;;ANTON V GULEVICH;;HARIPADA KHATUYA;;PAUL KRENITSKY;;FABRICE PIERRE;;ALINA SILINA;;JOE A TRAN;;JOHNNY UY;;YOSHIHIRO ISHIHARA;;TROY VICKERS,,https://lens.org/110-620-207-033-498,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,A61K31/529;;A61P11/00;;C07D515/08;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
166,EP,A2,EP 4225765 A2,147-103-734-658-577,2023-08-16,2023,EP 21830544 A,2021-10-06,US 202063088686 P;;US 2021/0053858 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;VICKERS TROY;;ZHOU JINGLAN,,https://lens.org/147-103-734-658-577,Patent Application,yes,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
167,WO,A3,WO 2022/076622 A3,001-848-768-321-990,2022-07-21,2022,US 2021/0053858 W,2021-10-06,US 202063088686 P,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;VICKERS TROY;;ZHOU JINGLAN;;GROOTENHUIS PETER,,https://lens.org/001-848-768-321-990,Search Report,yes,4,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
168,KR,A,KR 20230107725 A,022-329-094-743-587,2023-07-17,2023,KR 20237015292 A,2021-10-06,US 202063088686 P;;US 2021/0053858 W,2020-10-07,낭성 섬유증 막관통 전도도 조절자의 조절제,"JPEGpct01434.jpg70107 본 개시는 코어 구조 (I)을 갖는 낭성 섬유증 막관통 전도도 조절자(CFTR)의 조절제; 적어도 하나의 이러한 조절제를 함유하는 약학적 조성물; 이러한 조절제 및 약학적 조성물을 사용해, 낭성 섬유증을 포함하는 CFTR 매개 질환을 치료하는 방법; 이들 조절제를 사용하는 병용 약학적 조성물 및 병용 요법; 및 이러한 조절제를 제조하기 위한 프로세스 및 중간체를 제공한다.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;VICKERS TROY;;ZHOU JINGLAN,,https://lens.org/022-329-094-743-587,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/04;;A61K31/403;;A61K31/519;;A61K45/06;;A61P11/00;;A61P43/00;;C07D515/08;;C07D515/18,,0,0,,,,PENDING
169,CO,A2,CO 2023005006 A2,146-639-457-733-012,2023-09-08,2023,CO 2023005006 A,2023-04-20,US 2021/0053858 W;;US 202063088686 P,2020-10-07,Moduladores del regulador de la conductancia transmembrana de la fibrosis quística,"La descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura principal (I), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de enfermedades mediadas por CFTR, incluida la fibrosis quística, que usan tales moduladores y composiciones farmacéuticas, combinación de composiciones farmacéuticas y terapias combinadas que emplean estos moduladores y procesos de fabricación de tales moduladores.",VERTEX PHARMA,CLEVELAND THOMAS;;PIERRE FABRICE JEAN DENIS;;ANDERSON COREY DON;;COON TIMOTHY RICHARD;;GROOTENHUIS PETER (DECEASED);;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;DWIGHT TIMOTHY A;;FRIEMAN BRYAN A;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;MELILLO VITO;;SILINA ALINA;;UY JOHNNY;;FANNING LEV TYLER DEWEY;;GULEVICH ANTON V;;KHATUYA HARIPADA;;VALDEZ LINO;;TRAN JOE A;;VICKERS TROY,,https://lens.org/146-639-457-733-012,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
170,CA,A1,CA 3197683 A1,083-889-512-989-554,2022-04-14,2022,CA 3197683 A,2021-10-06,US 202063088686 P;;US 2021/0053858 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;VICKERS TROY;;ZHOU JINGLAN;;GROOTENHUIS PETER;;GULEVICH ANTON V,,https://lens.org/083-889-512-989-554,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
171,DO,A,DO P2023000067 A,118-054-603-827-609,2023-07-09,2023,DO 2023000067 A,2023-04-05,US 202063088686 P;;US 2021/0053858 W,2020-10-07,MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUÍSTICA,"La descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura principal (I), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de enfermedades mediadas por CFTR, incluida la fibrosis quística, que usan tales moduladores y composiciones farmacéuticas, combinación de composiciones farmacéuticas y terapias combinadas que emplean estos moduladores y procesos de fabricación de tales moduladores.",VERTEX PHARMA,MARK THOMAS MILLER;;THOMAS CLEVELAND;;BRYAN A FRIEMAN;;HARIPADA KHATUYA;;JOHNNY UY;;JINGLAN ZHOU;;JASON MCCARTNEY;;TIMOTHY RICHARD COON;;VIJAYALAKSMI ARUMUGAM;;JACLYN CHAU;;TIMOTHY A DWIGHT;;SARA SABINA HADIDA RUAH;;PAUL KRENITSKY;;VITO MELILLO;;LEV TYLER DEWEY FANNING;;ANTON V GULEVICH;;PRASUNA PARASELLI;;FABRICE PIERRE;;COREY DON ANDERSON;;JEREMY CLEMENS;;PETER GROOTENHUIS (FALLECIDO);;YOSHIHIRO ISHIHARA;;ALINA SILINA;;JOE A TRAN;;LINO VALDEZ;;ALEXANDER RUSELL ABELA;;TROY VICKERS;;SUNNY ABRAHAM,,https://lens.org/118-054-603-827-609,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,A61K31/529;;A61P11/00;;C07D515/08;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
172,WO,A2,WO 2022/076622 A2,182-609-112-220-244,2022-04-14,2022,US 2021/0053858 W,2021-10-06,US 202063088686 P,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;VICKERS TROY;;ZHOU JINGLAN;;GROOTENHUIS PETER,,https://lens.org/182-609-112-220-244,Patent Application,yes,29,5,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18;;C07D519/00,,12,8,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;007-364-858-655-289,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1002/jps.2600660104;;833720,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, 1990, pages 863 - 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50;;WUTS, P. G. M.: ""Greene's Protective Groups in Organic Synthesis: Fifth Edition"", 2014, JOHN WILEY AND SONS;;LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER",PENDING
173,CR,A,CR 20230198 A,177-856-820-968-947,2023-07-03,2023,CR 20230198 A,2021-10-06,US 202063088686 P;;US 2021/0053858 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"<br /> <br /> La descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura principal (I), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de enfermedades mediadas por CFTR, incluida la fibrosis quística, que usan tales moduladores y composiciones farmacéuticas, combinación de composiciones farmacéuticas y terapias combinadas que emplean estos moduladores y procesos de fabricación de tales moduladores.",VERTEX PHARMA,CLEMENS JEREMY;;GULEVICH ANTON V;;ISHIHARA YOSHIHIRO;;MILLER MARK THOMAS;;FANNING LEV TYLER DEWEY;;ABELA ALEXANDER RUSSELL;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;KHATUYA HARIPADA;;PARASELLI PRASUNA;;ANDERSON COREY DON;;FRIEMAN BRYAN A;;ZHOU JINGLAN;;MCCARTNEY JASON;;ABRAHAM SUNNY;;CHAU JACLYN;;CLEVELAND THOMAS;;MELILLO VITO;;VICKERS TROY;;KRENITSKY PAUL;;ARUMUGAM VIJAYALAKSMI;;PIERRE FABRICE;;TRAN JOE A;;SILINA ALINA;;DWIGHT TIMOTHY A;;COON TIMOTHY RICHARD;;UY JOHNNY;;VALDEZ LINO,,https://lens.org/177-856-820-968-947,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,,,0,0,,,,PENDING
174,EC,A,EC SP23033092 A,183-786-134-594-769,2023-06-30,2023,EC DI202333092 A,2023-05-04,US 202063088686 P,2020-10-07,MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUÍSTICA,"La descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura principal (I), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de enfermedades mediadas por CFTR, incluida la fibrosis quística, que usan tales moduladores y composiciones farmacéuticas, combinación de composiciones farmacéuticas y terapias combinadas que emplean estos moduladores y procesos de fabricación de tales moduladores",VERTEX PHARMA,MCCARTNEY JASON;;KHATUYA HARIPADA;;MILLER MARK THOMAS;;TRAN JOE;;ISHIHARA YOSHIHIRO;;HADIDA RUAH SARA SABINA;;ANDERSON COREY DON;;MELILLO VITO;;CHAU JACLYN;;ARUMUGAM VIJAYALAKSMI;;PIERRE FABRICE;;PARASELLI PRASUNA;;COON TIMOTHY RICHARD;;GROOTENHUIS PETER (FALLECIDO);;SILINA ALINA;;CLEVELAND THOMAS;;VALDEZ LINO;;KRENITSKY PAUL;;FRIEMAN BRYAN A;;DWIGHT TIMOTHY A;;ZHOU JINGLAN;;UY JOHNNY;;VICKERS TROY;;FANNING LEV TYLER DEWEY;;CLEMENS JEREMY;;ABRAHAM SUNNY;;GULEVICH ANTON V;;ABELA ALEXANDER RUSSELL,,https://lens.org/183-786-134-594-769,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
175,TW,A,TW 202229298 A,150-340-245-319-803,2022-08-01,2022,TW 110137345 A,2021-10-07,US 202063088686 P,2020-10-07,Modulators of Cystic Fibrosis Transmembrane Conductance Regulator,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;VICKERS TROY;;ZHOU JINGLAN,,https://lens.org/150-340-245-319-803,Patent of Addition,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/04;;A61K31/519;;A61P43/00,,0,0,,,,PENDING
176,AU,A8,AU 2021/358512 A8,107-200-287-528-220,2023-05-25,2023,AU 2021/358512 A,2021-10-06,US 202063088686 P;;US 2021/0053858 W,2020-10-07,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;VICKERS TROY;;ZHOU JINGLAN,,https://lens.org/107-200-287-528-220,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
177,PE,A1,PE 20231108 A1,111-228-927-053-104,2023-07-19,2023,PE 2023001370 A,2021-10-06,US 202063088686 P;;US 2021/0053858 W,2020-10-07,MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUISTICA,"SE REFIERE A COMPUESTOS MACROCICLICOS DE FORMULA (I) DONDE LOS ANILLOS A Y B, R3, R4, R5, W1, W2, L1, L2, Z Y RYN SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS: (11R)-11-(CICLOPENTILMETIL)-6-(2,6-DIMETILFENIL)-12-[(6-ISOPROPIL-5-METIL-PIRROLO[2,3-B]PIRAZIN-3-IL)METIL]-2,2-DIOXO-9-OXA-2 lamda 6-TIA-3,5,12,19-TETRAZATRICICLO[12.3.1.14,8]NONADECA-1(18),4(19),5,7,14,16-HEXAEN-13-ONA; 11-(3,3-DIMETILCICLOBUTIL)-6-(2,6-DIMETILFENIL)-12-[[6-[(2R)-2-METILPIRROLIDIN-1-IL]PIRAZIN-2-IL]METIL]-2,2-DIOXO-9-OXA-2 lamda 6-TIA-3,5,12,19-TETRAZATRICICLO[12.3.1.14,8]NONADECA-1(18),4(19),5,7,14,16-HEXAEN-13-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUISTICA (CFTR) SIENDO UTILES EN EL TRATAMIENTO DE FIBROSIS QUISTICA.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRIAN A;;GROOTENHUIS PETER;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;VICKERS TROY;;ZHOU JINGLAN,,https://lens.org/111-228-927-053-104,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
178,AR,A1,AR 123708 A1,085-093-061-007-337,2023-01-04,2023,AR P210102778 A,2021-10-07,US 202063088686 P,2020-10-07,MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANARIO DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores.",VERTEX PHARMA,MCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM SUNNY;;ANDERSON COREY DON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV TYLER DEWEY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER FALLECIDO;;GULEVIVH ANTON V;;HADIDA RUAH SARA SABINA;;ISHIHARA YOSHIHIRO;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LINO;;VICKERS TROY;;ZHOU JINGLAN,,https://lens.org/085-093-061-007-337,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D515/08;;A61K31/529;;A61P11/00;;C07D515/18;;C07D519/00,,0,0,,,,PENDING
179,UY,A,UY 39457 A,014-600-954-705-624,2022-05-31,2022,UY 39457 A,2021-10-07,US 202063088686 P,2020-10-07,MODULADORES DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANARIO DE LA FIBROSIS QUÍSTICA,"Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores",VERTEX PHARMA,GROOTENHUIS PETER;;SARA SABINA HADIDA RUAH;;CLEVELAND THOMAS;;BRYAN A FRIEMAN;;KHATUYA HARIPADA;;MELILLO VITO;;ZHOU JINGLAN;;ALEXANDER RUSSELL ABELA;;MARK THOMAS MILLER;;UY JOHNNY;;MCCARTNEY JASON;;ABRAHAM SUNNY;;COREY DON ANDERSON;;ARUMUGAM VIJAYALAKSMI;;CHAU JACLYN;;CLEMENS JEREMY;;TIMOTHY A DWIGHT;;ISHIHARA YOSHIHIRO;;KRENITSKY PAUL;;PIERRE FABRICE;;SILINA ALINA;;TIMOTHY RICHARD COON;;LEV TYLER DEWEY FANNING;;ANTON V GULEVICH;;JOE A TRAN;;VALDEZ LINO;;VICKERS TROY;;PARASELLI PRASUNA,,https://lens.org/014-600-954-705-624,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,A61K31/36;;A61K31/404;;A61K31/443;;A61K31/47;;A61K31/519;;A61P11/00;;C07D515/04,,0,0,,,,PENDING
180,CN,A,CN 116601158 A,027-159-923-844-098,2023-08-15,2023,CN 202180082021 A,2021-10-06,US 202063088686 P;;US 2021/0053858 W,2020-10-07,Modulators of cystic fibrosis transmembrane conductance regulators,"The present disclosure provides: a modulator of cystic fibrosis transmembrane conductance regulatory factor (CFTR), the modulator having a core structure (I); pharmaceutical compositions containing at least one such modulator; methods of treating CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions; combination pharmaceutical compositions and combination therapies employing these modulators; and processes and intermediates for preparing such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER R;;ABRAHAM SANTOSH;;ANDERSON CHRISTOPHER D;;ARUMUGAM VIVEK;;ZHOU JIACHENG;;CLEMENS JOHN;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV T D;;FREEMAN BRYAN A;;GROOTENHUIS PETER;;GUREVICH ALEKSANDR V;;HADIDA RUAH SARA S;;ISHIHARA YASUO;;KATUJA HANNU;;KRENICKI PETER;;MELILLO VITO;;MILLER MARK T;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALESSANDRO;;TRAN JAMES A;;UY JOHNNY;;VALDEZ LUIS;;VICKERS THOMAS;;ZHOU JIACHENG,,https://lens.org/027-159-923-844-098,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D519/00,,0,0,,,,PENDING
